lomenet65的个人主页 - 老虎社区

lomenet65

lomenet65

暂无个人介绍

IP属地：未知

36关注

2粉丝

0主题

0勋章

2021-12-07

Great ariticle, would you like to share it?

@Buy_Sell:🚀【12月7日】市场看淡病毒风险，中概多数反弹，今天买点啥？

2021-12-07

Great ariticle, would you like to share it?

@JayceLee:Options Trade Ideas

2021-12-07

Nice

抱歉，原内容已删除

2021-12-02

Great ariticle, would you like to share it?

Novartis sees annual sales growth of 4% until 2026<blockquote>诺华预计到2026年销售额年增长4%</blockquote>

2021-12-02

Great ariticle, would you like to share it?

Dow Jones futures rose nearly 1%, S&P 500 futures rose 0.85%, Nasdaq 100 futures rose 0.64%.<blockquote>道琼斯期货涨近1%，标普500期货涨0.85%，纳斯达克100期货涨0.64%。</blockquote>

2021-12-02

Great ariticle, would you like to share it?

What Happened To AMC Entertainment's Stock And When Will It Recover? A Technical Analysis<blockquote>AMC院线的股票怎么了，什么时候才能恢复？技术分析</blockquote>

2021-12-02

Great ariticle, would you like to share it?

Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Variant<blockquote>临床前数据表明Sotrovimab保留了针对关键奥密克戎突变、新新型冠状病毒变种的活性</blockquote>

2021-12-02

Nice

Dow Jones futures rose nearly 1%, S&P 500 futures rose 0.85%, Nasdaq 100 futures rose 0.64%.<blockquote>道琼斯期货涨近1%，标普500期货涨0.85%，纳斯达克100期货涨0.64%。</blockquote>

2021-11-29

Great ariticle, would you like to share it?

@Buy_Sell:🔥【11月29日】看本周关键事件，聊今日交易计划

2021-11-29

Great ariticle, would you like to share it?

抱歉，原内容已删除

2021-11-29

Great ariticle, would you like to share it?

November jobs report: What to know this week<blockquote>11月就业报告：本周需要了解什么</blockquote>

2021-11-29

Great ariticle, would you like to share it?

抱歉，原内容已删除

2021-11-29

Great ariticle, would you like to share it?

India's Paytm falls as net loss widens on higher expense<blockquote>费用增加导致净亏损扩大，印度Paytm股价下跌</blockquote>

2021-11-29

Nice

Digital Core REIT to raise $600 mln in Singapore's biggest IPO this year<blockquote>Digital Core REIT将在新加坡今年最大的IPO中筹集6亿美元</blockquote>

2021-11-25

Great ariticle, would you like to share it?

@新能源洒水车:ET7的爆款潜质！

2021-11-25

Great ariticle, would you like to share it?

抱歉，原内容已删除

2021-11-25

Nice

Dyson terminates relationship with Malaysian supplier ATA over labour<blockquote>戴森因劳工问题终止与马来西亚供应商ATA的关系</blockquote>

2021-11-25

Great ariticle, would you like to share it?

抱歉，原内容已删除

2021-11-20

Great ariticle, would you like to share it?

Intuit jumped over 12% in morning trading after showing its better than expected financial report<blockquote>Intuit公布好于预期的财务报告后早盘上涨逾12%</blockquote>

2021-11-20

Nice

FuelCell stock jumped 6% in morning trading<blockquote>FuelCell股价早盘上涨6%</blockquote>

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4099680250879430","uuid":"4099680250879430","gmtCreate":1636586685899,"gmtModify":1636855560319,"name":"lomenet65","pinyin":"lomenet65","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/a92a300242412a0d7cd11dbac51daaab","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":36,"tweetSize":24,"questionSize":0,"limitLevel":999,"accountStatus":3,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"wearingSort":0}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":606507133,"gmtCreate":1638890108532,"gmtModify":1638890108532,"author":{"id":"4099680250879430","authorId":"4099680250879430","name":"lomenet65","avatar":"https://static.tigerbbs.com/a92a300242412a0d7cd11dbac51daaab","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099680250879430","idStr":"4099680250879430"},"themes":[],"title":"","htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606507133","repostId":"606159835","repostType":1,"repost":{"id":606159835,"gmtCreate":1638845497223,"gmtModify":1638931778801,"author":{"id":"3527667596890271","authorId":"3527667596890271","name":"Buy_Sell","avatar":"https://static.tigerbbs.com/a5f0ed79a338c758a22e0b4ea13bf9d2","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3527667596890271","idStr":"3527667596890271"},"themes":[],"title":"🚀【12月7日】市场看淡病毒风险，中概多数反弹，今天买点啥？","htmlText":"聊聊今日份的交易想法，包括对于大盘走势后续的看法？看涨/看跌哪只股票、晒晒单等等。 港股市场 12月7日，港股三大指数大幅高开，恒指涨1.52%，国指涨1.62%，恒生科技指数涨2.07%。 恒生科技指数开涨超2%，科技股普遍上扬；<a target=\"_blank\" href=\"https://laohu8.com/S/09988\">$阿里巴巴-SW(09988)$</a> 开涨8.25%，隔夜其<a target=\"_blank\" href=\"https://laohu8.com/S/BABA\">$阿里巴巴(BABA)$</a> 美股收涨逾10%；<a target=\"_blank\" href=\"https://laohu8.com/S/09888\">$百度集团-SW(09888)$</a> 涨7.5%，<a target=\"_blank\" href=\"https://laohu8.com/S/03690\">$美团-W(03690)$</a> 涨超3%，<a target=\"_blank\" href=\"https://laohu8.com/S/00700\">$腾讯控股(00700)$</a> 、<a target=\"_blank\" href=\"https://laohu8.com/S/01024\">$快手-W(01024)$</a> 均涨超2%； 港股市场汽车股高开。其中，<a target=\"_blank\" href=\"https://laohu8.com/S/00708\">$恒大汽车(00708)$</a> 涨超5%，五菱汽车、理想汽车-W涨超3%，吉利汽车、长城汽车涨超2%，广汽集团、小鹏汽车-W、比亚迪等均涨超1%； 中国恒大开涨6.63%，昨日公司公告称决议设立中国恒大集团风险化解委员会；","listText":"聊聊今日份的交易想法，包括对于大盘走势后续的看法？看涨/看跌哪只股票、晒晒单等等。 港股市场 12月7日，港股三大指数大幅高开，恒指涨1.52%，国指涨1.62%，恒生科技指数涨2.07%。 恒生科技指数开涨超2%，科技股普遍上扬；<a target=\"_blank\" href=\"https://laohu8.com/S/09988\">$阿里巴巴-SW(09988)$</a> 开涨8.25%，隔夜其<a target=\"_blank\" href=\"https://laohu8.com/S/BABA\">$阿里巴巴(BABA)$</a> 美股收涨逾10%；<a target=\"_blank\" href=\"https://laohu8.com/S/09888\">$百度集团-SW(09888)$</a> 涨7.5%，<a target=\"_blank\" href=\"https://laohu8.com/S/03690\">$美团-W(03690)$</a> 涨超3%，<a target=\"_blank\" href=\"https://laohu8.com/S/00700\">$腾讯控股(00700)$</a> 、<a target=\"_blank\" href=\"https://laohu8.com/S/01024\">$快手-W(01024)$</a> 均涨超2%； 港股市场汽车股高开。其中，<a target=\"_blank\" href=\"https://laohu8.com/S/00708\">$恒大汽车(00708)$</a> 涨超5%，五菱汽车、理想汽车-W涨超3%，吉利汽车、长城汽车涨超2%，广汽集团、小鹏汽车-W、比亚迪等均涨超1%； 中国恒大开涨6.63%，昨日公司公告称决议设立中国恒大集团风险化解委员会；","text":"聊聊今日份的交易想法，包括对于大盘走势后续的看法？看涨/看跌哪只股票、晒晒单等等。 港股市场 12月7日，港股三大指数大幅高开，恒指涨1.52%，国指涨1.62%，恒生科技指数涨2.07%。 恒生科技指数开涨超2%，科技股普遍上扬；$阿里巴巴-SW(09988)$ 开涨8.25%，隔夜其$阿里巴巴(BABA)$ 美股收涨逾10%；$百度集团-SW(09888)$ 涨7.5%，$美团-W(03690)$ 涨超3%，$腾讯控股(00700)$ 、$快手-W(01024)$ 均涨超2%； 港股市场汽车股高开。其中，$恒大汽车(00708)$ 涨超5%，五菱汽车、理想汽车-W涨超3%，吉利汽车、长城汽车涨超2%，广汽集团、小鹏汽车-W、比亚迪等均涨超1%； 中国恒大开涨6.63%，昨日公司公告称决议设立中国恒大集团风险化解委员会；","images":[{"img":"https://static.tigerbbs.com/bef7c1191d263cbe5867f805bf92d02d","width":"240","height":"240"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606159835","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"subType":2,"comments":[],"imageCount":2,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2499,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606502862,"gmtCreate":1638889918652,"gmtModify":1638889918756,"author":{"id":"4099680250879430","authorId":"4099680250879430","name":"lomenet65","avatar":"https://static.tigerbbs.com/a92a300242412a0d7cd11dbac51daaab","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099680250879430","idStr":"4099680250879430"},"themes":[],"title":"","htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606502862","repostId":"873111072","repostType":1,"repost":{"id":873111072,"gmtCreate":1636879722614,"gmtModify":1636940228507,"author":{"id":"3572212908677301","authorId":"3572212908677301","name":"JayceLee","avatar":"https://static.tigerbbs.com/697be0b87a439db9bb3e696889951c59","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3572212908677301","idStr":"3572212908677301"},"themes":[],"title":"Options Trade Ideas","htmlText":"Weekly Trade Ideas Boeing (<a target=\"_blank\" href=\"https://laohu8.com/S/BA\">$波音(BA)$</a>)The weekly chart is currently closed near the downtrend line. Watch for a potential breakout or rejection back to the support zone below which held nicely multiple times.In the daily chart, the price has been consolidating between 217 to 227.If breakthrough 225.24,&nbsp;my target zone is 235-239.67.If fall beyond 212.79, my target zone is 204.80-207.03.iShares Russell 2000 ETF (<a target=\"_blank\" href=\"https://laohu8.com/S/IWM\">$罗素2000指数ETF(IWM)$</a>)After a breakout from close to 1-year consolidation, we are seeing a pullback from the all-time high. Watch for trend continuation higher or falling back to retest the breakout level.In the daily chart, we are seeing 2 inside bars as the price consolidate","listText":"Weekly Trade Ideas Boeing (<a target=\"_blank\" href=\"https://laohu8.com/S/BA\">$波音(BA)$</a>)The weekly chart is currently closed near the downtrend line. Watch for a potential breakout or rejection back to the support zone below which held nicely multiple times.In the daily chart, the price has been consolidating between 217 to 227.If breakthrough 225.24,&nbsp;my target zone is 235-239.67.If fall beyond 212.79, my target zone is 204.80-207.03.iShares Russell 2000 ETF (<a target=\"_blank\" href=\"https://laohu8.com/S/IWM\">$罗素2000指数ETF(IWM)$</a>)After a breakout from close to 1-year consolidation, we are seeing a pullback from the all-time high. Watch for trend continuation higher or falling back to retest the breakout level.In the daily chart, we are seeing 2 inside bars as the price consolidate","text":"Weekly Trade Ideas Boeing ($波音(BA)$)The weekly chart is currently closed near the downtrend line. Watch for a potential breakout or rejection back to the support zone below which held nicely multiple times.In the daily chart, the price has been consolidating between 217 to 227.If breakthrough 225.24, my target zone is 235-239.67.If fall beyond 212.79, my target zone is 204.80-207.03.iShares Russell 2000 ETF ($罗素2000指数ETF(IWM)$)After a breakout from close to 1-year consolidation, we are seeing a pullback from the all-time high. Watch for trend continuation higher or falling back to retest the breakout level.In the daily chart, we are seeing 2 inside bars as the price consolidate","images":[{"img":"https://static.tigerbbs.com/f71b745209d69116541a279c1a67aafd","width":"688","height":"318"},{"img":"https://static.tigerbbs.com/b284906dc8d3cf7e9e8fc7101fad62c3","width":"688","height":"318"},{"img":"https://static.tigerbbs.com/649c8568e1b2d907f88e482ea097946d","width":"688","height":"297"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/873111072","isVote":2,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"vote":{"id":1604,"gmtBegin":1636879722613,"gmtEnd":1637370026856,"type":1,"upper":3,"title":"Which idea you like?","choices":[{"id":5883,"sort":1,"name":"BA","userSize":70,"voted":false},{"id":5884,"sort":2,"name":"IWM","userSize":20,"voted":false},{"id":5885,"sort":3,"name":"NIO","userSize":107,"voted":false},{"id":5886,"sort":4,"name":"TDOC","userSize":52,"voted":false},{"id":5887,"sort":5,"name":"XPEV","userSize":56,"voted":false},{"id":5888,"sort":6,"name":"ZM","userSize":25,"voted":false}]},"comments":[],"imageCount":11,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2881,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606508423,"gmtCreate":1638889763914,"gmtModify":1638889763970,"author":{"id":"4099680250879430","authorId":"4099680250879430","name":"lomenet65","avatar":"https://static.tigerbbs.com/a92a300242412a0d7cd11dbac51daaab","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099680250879430","idStr":"4099680250879430"},"themes":[],"title":"","htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606508423","repostId":"2189476639","repostType":2,"isVote":1,"tweetType":1,"viewCount":1906,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603565331,"gmtCreate":1638429308826,"gmtModify":1638429308914,"author":{"id":"4099680250879430","authorId":"4099680250879430","name":"lomenet65","avatar":"https://static.tigerbbs.com/a92a300242412a0d7cd11dbac51daaab","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099680250879430","idStr":"4099680250879430"},"themes":[],"title":"","htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603565331","repostId":"1170912005","repostType":4,"repost":{"id":"1170912005","kind":"news","pubTimestamp":1638427945,"share":"https://www.laohu8.com/m/news/1170912005?lang=zh_CN&edition=full","pubTime":"2021-12-02 14:52","market":"us","language":"en","title":"Novartis sees annual sales growth of 4% until 2026<blockquote>诺华预计到2026年销售额年增长4%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1170912005","media":"Reuters","summary":"Swiss drugmaker Novartis is confident to reach a core margin in innovative medicines in the high 30s","content":"<p>Swiss drugmaker Novartis&nbsp;is confident to reach a core margin in innovative medicines in the high 30s by 2026 and grow sales by 4% each year until the end of that period, the company said in a presentation on Thursday.</p><p><blockquote>瑞士制药商诺华在周四的一次演讲中表示，该公司有信心到2026年将创新药物的核心利润率提高到30%以上，并在此期间结束前每年增长4%。</blockquote></p><p> Novartis added it had up to 20 assets in its pipeline with approval expected by 2026 that had the potential to generate at least 1$ billion in sales.</p><p><blockquote>诺华补充说，其管道中有多达20项资产，预计到2026年将获得批准，这些资产有可能产生至少10亿美元的销售额。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis sees annual sales growth of 4% until 2026<blockquote>诺华预计到2026年销售额年增长4%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis sees annual sales growth of 4% until 2026<blockquote>诺华预计到2026年销售额年增长4%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-12-02 14:52</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Swiss drugmaker Novartis&nbsp;is confident to reach a core margin in innovative medicines in the high 30s by 2026 and grow sales by 4% each year until the end of that period, the company said in a presentation on Thursday.</p><p><blockquote>瑞士制药商诺华在周四的一次演讲中表示，该公司有信心到2026年将创新药物的核心利润率提高到30%以上，并在此期间结束前每年增长4%。</blockquote></p><p> Novartis added it had up to 20 assets in its pipeline with approval expected by 2026 that had the potential to generate at least 1$ billion in sales.</p><p><blockquote>诺华补充说，其管道中有多达20项资产，预计到2026年将获得批准，这些资产有可能产生至少10亿美元的销售额。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/business/novartis-sees-annual-sales-growth-4-until-2026-2021-12-02/\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVS":"诺华"},"source_url":"https://www.reuters.com/business/novartis-sees-annual-sales-growth-4-until-2026-2021-12-02/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170912005","content_text":"Swiss drugmaker Novartis is confident to reach a core margin in innovative medicines in the high 30s by 2026 and grow sales by 4% each year until the end of that period, the company said in a presentation on Thursday.\nNovartis added it had up to 20 assets in its pipeline with approval expected by 2026 that had the potential to generate at least 1$ billion in sales.","news_type":1,"symbols_score_info":{"NVS":0.9}},"isVote":1,"tweetType":1,"viewCount":1747,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603565918,"gmtCreate":1638429294288,"gmtModify":1638429294358,"author":{"id":"4099680250879430","authorId":"4099680250879430","name":"lomenet65","avatar":"https://static.tigerbbs.com/a92a300242412a0d7cd11dbac51daaab","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099680250879430","idStr":"4099680250879430"},"themes":[],"title":"","htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603565918","repostId":"1101300146","repostType":4,"repost":{"id":"1101300146","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638428501,"share":"https://www.laohu8.com/m/news/1101300146?lang=zh_CN&edition=full","pubTime":"2021-12-02 15:01","market":"us","language":"en","title":"Dow Jones futures rose nearly 1%, S&P 500 futures rose 0.85%, Nasdaq 100 futures rose 0.64%.<blockquote>道琼斯期货涨近1%，标普500期货涨0.85%，纳斯达克100期货涨0.64%。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1101300146","media":"Tiger Newspress","summary":"Dow Jones futures rose nearly 1%, S&P 500 futures rose 0.85%, Nasdaq 100 futures rose 0.64%.","content":"<p>Dow Jones futures rose&nbsp;nearly 1%, S&amp;P 500 futures rose 0.85%, Nasdaq 100 futures rose 0.64%.<img src=\"https://static.tigerbbs.com/7cc5fbc2c078d2e811d0be03d2c4950f\" tg-width=\"542\" tg-height=\"184\" width=\"100%\" height=\"auto\"></p><p><blockquote>道琼斯期货涨近1%，标普500期货涨0.85%，纳斯达克100期货涨0.64%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dow Jones futures rose nearly 1%, S&P 500 futures rose 0.85%, Nasdaq 100 futures rose 0.64%.<blockquote>道琼斯期货涨近1%，标普500期货涨0.85%，纳斯达克100期货涨0.64%。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDow Jones futures rose nearly 1%, S&P 500 futures rose 0.85%, Nasdaq 100 futures rose 0.64%.<blockquote>道琼斯期货涨近1%，标普500期货涨0.85%，纳斯达克100期货涨0.64%。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-02 15:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Dow Jones futures rose&nbsp;nearly 1%, S&amp;P 500 futures rose 0.85%, Nasdaq 100 futures rose 0.64%.<img src=\"https://static.tigerbbs.com/7cc5fbc2c078d2e811d0be03d2c4950f\" tg-width=\"542\" tg-height=\"184\" width=\"100%\" height=\"auto\"></p><p><blockquote>道琼斯期货涨近1%，标普500期货涨0.85%，纳斯达克100期货涨0.64%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101300146","content_text":"Dow Jones futures rose nearly 1%, S&P 500 futures rose 0.85%, Nasdaq 100 futures rose 0.64%.","news_type":1,"symbols_score_info":{"ESmain":0.9,"YMmain":0.9,"NQmain":0.9}},"isVote":1,"tweetType":1,"viewCount":1696,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603562412,"gmtCreate":1638429268037,"gmtModify":1638429268214,"author":{"id":"4099680250879430","authorId":"4099680250879430","name":"lomenet65","avatar":"https://static.tigerbbs.com/a92a300242412a0d7cd11dbac51daaab","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099680250879430","idStr":"4099680250879430"},"themes":[],"title":"","htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603562412","repostId":"1187737792","repostType":4,"repost":{"id":"1187737792","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1638429050,"share":"https://www.laohu8.com/m/news/1187737792?lang=zh_CN&edition=full","pubTime":"2021-12-02 15:10","market":"us","language":"en","title":"What Happened To AMC Entertainment's Stock And When Will It Recover? A Technical Analysis<blockquote>AMC院线的股票怎么了，什么时候才能恢复？技术分析</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1187737792","media":"Benzinga","summary":"AMC Entertainment Holdings Inc. shares are trading lower Wednesday, as concerns over COVID-19 varian","content":"<p><b>AMC Entertainment Holdings Inc.</b>&nbsp;shares are trading lower Wednesday, as concerns over COVID-19 variant omicron weighs on the outlook for theater traffic in the future. Shutdowns in theaters in the beginning of 2020 could continue if the omicron variant extends the pandemic.</p><p><blockquote><b>AMC院线控股公司。</b>由于对COVID-19变种奥密克戎的担忧影响了未来影院客流量的前景，周三股价走低。如果奥密克戎变种延长疫情，2020年初影院的关闭可能会继续。</blockquote></p><p> AMC Entertainment closed down 15.8% at $28.57.</p><p><blockquote>AMC院线收跌15.8%，报28.57美元。</blockquote></p><p> <b>AMC Entertainment Daily Chart Analysis</b></p><p><blockquote><b>AMC院线日线图分析</b></blockquote></p><p> <ul>  <li>The stock has fallen below support in what technical traders call a pennant pattern.</li>  <li>The stock was seeing condensed highs and lows and neared the end of the pennant pattern looking for a breakout, but fell below pattern support seeing a strong bearish move.</li>  <li>The stock trades below the 50-day moving average (green) and fell below the 200-day moving average (blue) Wednesday, indicating the sentiment in the stock looks to be turning more bearish.</li>  <li>Each of these moving averages may hold as an area of resistance in the future.</li>  <li>The Relative Strength Index (RSI) saw a steep drop off and pushed down to 25 on the level Wednesday. This shows the stock is now in the oversold range and is seeing much more selling pressure than buying pressure.</li> </ul> <img src=\"https://static.tigerbbs.com/e5dad36850a74a6c9fbdda0d9c7d68f4\" tg-width=\"2400\" tg-height=\"1236\" width=\"100%\" height=\"auto\"></p><p><blockquote><ul><li>该股已跌破技术交易员看涨期权三角旗形态的支撑位。</li><li>该股出现了浓缩的高点和低点，并接近三角旗形态的末端寻求突破，但跌破形态支撑，出现了强劲的看跌走势。</li><li>该股周三交易价格低于50日移动平均线（绿色），并跌破200日移动平均线（蓝色），表明该股的情绪似乎变得更加看跌。</li><li>这些移动平均线中的每一条都可能在未来成为阻力区域。</li><li>相对强弱指数（RSI）大幅下跌，周三跌至25。这表明该股目前处于超卖区间，抛售压力远大于买入压力。</li></ul></blockquote></p><p> <b>What’s Next For AMC Entertainment?</b></p><p><blockquote><b>AMC院线的下一步是什么？</b></blockquote></p><p> Bullish traders want AMC to bounce and start to head higher while being able to form higher lows. Higher lows are key in showing the stock is ready to turnaround and start to move higher once again. Bulls also want to see the price cross back above the moving averages for the sentiment to turn bullish once again.</p><p><blockquote>看涨交易者希望AMC反弹并开始走高，同时能够形成更高的低点。较高的低点是表明该股已准备好扭亏为盈并开始再次走高的关键。多头还希望看到价格回到移动平均线上方，以便情绪再次转向看涨。</blockquote></p><p> Bearish traders look to have taken control of the stock after the drop below the pattern support and the moving averages. The drop below the moving averages shows a bearish sentiment beginning in the stock. If the stock can hold below the pattern support and the moving averages, bears can maintain a hold on the stock.</p><p><blockquote>在跌破形态支撑位和移动平均线后，看跌交易者似乎已经控制了该股。跌破移动平均线表明该股开始出现看跌情绪。如果该股能够保持在形态支撑和移动平均线以下，空头可以持有该股。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What Happened To AMC Entertainment's Stock And When Will It Recover? A Technical Analysis<blockquote>AMC院线的股票怎么了，什么时候才能恢复？技术分析</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat Happened To AMC Entertainment's Stock And When Will It Recover? A Technical Analysis<blockquote>AMC院线的股票怎么了，什么时候才能恢复？技术分析</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-12-02 15:10</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>AMC Entertainment Holdings Inc.</b>&nbsp;shares are trading lower Wednesday, as concerns over COVID-19 variant omicron weighs on the outlook for theater traffic in the future. Shutdowns in theaters in the beginning of 2020 could continue if the omicron variant extends the pandemic.</p><p><blockquote><b>AMC院线控股公司。</b>由于对COVID-19变种奥密克戎的担忧影响了未来影院客流量的前景，周三股价走低。如果奥密克戎变种延长疫情，2020年初影院的关闭可能会继续。</blockquote></p><p> AMC Entertainment closed down 15.8% at $28.57.</p><p><blockquote>AMC院线收跌15.8%，报28.57美元。</blockquote></p><p> <b>AMC Entertainment Daily Chart Analysis</b></p><p><blockquote><b>AMC院线日线图分析</b></blockquote></p><p> <ul>  <li>The stock has fallen below support in what technical traders call a pennant pattern.</li>  <li>The stock was seeing condensed highs and lows and neared the end of the pennant pattern looking for a breakout, but fell below pattern support seeing a strong bearish move.</li>  <li>The stock trades below the 50-day moving average (green) and fell below the 200-day moving average (blue) Wednesday, indicating the sentiment in the stock looks to be turning more bearish.</li>  <li>Each of these moving averages may hold as an area of resistance in the future.</li>  <li>The Relative Strength Index (RSI) saw a steep drop off and pushed down to 25 on the level Wednesday. This shows the stock is now in the oversold range and is seeing much more selling pressure than buying pressure.</li> </ul> <img src=\"https://static.tigerbbs.com/e5dad36850a74a6c9fbdda0d9c7d68f4\" tg-width=\"2400\" tg-height=\"1236\" width=\"100%\" height=\"auto\"></p><p><blockquote><ul><li>该股已跌破技术交易员看涨期权三角旗形态的支撑位。</li><li>该股出现了浓缩的高点和低点，并接近三角旗形态的末端寻求突破，但跌破形态支撑，出现了强劲的看跌走势。</li><li>该股周三交易价格低于50日移动平均线（绿色），并跌破200日移动平均线（蓝色），表明该股的情绪似乎变得更加看跌。</li><li>这些移动平均线中的每一条都可能在未来成为阻力区域。</li><li>相对强弱指数（RSI）大幅下跌，周三跌至25。这表明该股目前处于超卖区间，抛售压力远大于买入压力。</li></ul></blockquote></p><p> <b>What’s Next For AMC Entertainment?</b></p><p><blockquote><b>AMC院线的下一步是什么？</b></blockquote></p><p> Bullish traders want AMC to bounce and start to head higher while being able to form higher lows. Higher lows are key in showing the stock is ready to turnaround and start to move higher once again. Bulls also want to see the price cross back above the moving averages for the sentiment to turn bullish once again.</p><p><blockquote>看涨交易者希望AMC反弹并开始走高，同时能够形成更高的低点。较高的低点是表明该股已准备好扭亏为盈并开始再次走高的关键。多头还希望看到价格回到移动平均线上方，以便情绪再次转向看涨。</blockquote></p><p> Bearish traders look to have taken control of the stock after the drop below the pattern support and the moving averages. The drop below the moving averages shows a bearish sentiment beginning in the stock. If the stock can hold below the pattern support and the moving averages, bears can maintain a hold on the stock.</p><p><blockquote>在跌破形态支撑位和移动平均线后，看跌交易者似乎已经控制了该股。跌破移动平均线表明该股开始出现看跌情绪。如果该股能够保持在形态支撑和移动平均线以下，空头可以持有该股。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1187737792","content_text":"AMC Entertainment Holdings Inc. shares are trading lower Wednesday, as concerns over COVID-19 variant omicron weighs on the outlook for theater traffic in the future. Shutdowns in theaters in the beginning of 2020 could continue if the omicron variant extends the pandemic.\nAMC Entertainment closed down 15.8% at $28.57.\nAMC Entertainment Daily Chart Analysis\n\nThe stock has fallen below support in what technical traders call a pennant pattern.\nThe stock was seeing condensed highs and lows and neared the end of the pennant pattern looking for a breakout, but fell below pattern support seeing a strong bearish move.\nThe stock trades below the 50-day moving average (green) and fell below the 200-day moving average (blue) Wednesday, indicating the sentiment in the stock looks to be turning more bearish.\nEach of these moving averages may hold as an area of resistance in the future.\nThe Relative Strength Index (RSI) saw a steep drop off and pushed down to 25 on the level Wednesday. This shows the stock is now in the oversold range and is seeing much more selling pressure than buying pressure.\n\n\nWhat’s Next For AMC Entertainment?\nBullish traders want AMC to bounce and start to head higher while being able to form higher lows. Higher lows are key in showing the stock is ready to turnaround and start to move higher once again. Bulls also want to see the price cross back above the moving averages for the sentiment to turn bullish once again.\nBearish traders look to have taken control of the stock after the drop below the pattern support and the moving averages. The drop below the moving averages shows a bearish sentiment beginning in the stock. If the stock can hold below the pattern support and the moving averages, bears can maintain a hold on the stock.","news_type":1,"symbols_score_info":{"AMC":0.9}},"isVote":1,"tweetType":1,"viewCount":2383,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603562825,"gmtCreate":1638429255373,"gmtModify":1638429256360,"author":{"id":"4099680250879430","authorId":"4099680250879430","name":"lomenet65","avatar":"https://static.tigerbbs.com/a92a300242412a0d7cd11dbac51daaab","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099680250879430","idStr":"4099680250879430"},"themes":[],"title":"","htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603562825","repostId":"1195275859","repostType":4,"repost":{"id":"1195275859","kind":"news","pubTimestamp":1638429111,"share":"https://www.laohu8.com/m/news/1195275859?lang=zh_CN&edition=full","pubTime":"2021-12-02 15:11","market":"us","language":"en","title":"Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Variant<blockquote>临床前数据表明Sotrovimab保留了针对关键奥密克戎突变、新新型冠状病毒变种的活性</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1195275859","media":"GlobeNewswire","summary":"LONDON and SAN FRANCISCO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and ","content":"<p>LONDON and SAN FRANCISCO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced an update tobioRxiv, a preprint server, with preclinical data demonstrating that sotrovimab, an investigational monoclonal antibody, retains activity against key mutations1of the new Omicron SARS-CoV-2 variant (B.1.1.529), including those found in the binding site of sotrovimab. These data were generated through pseudo-virus testing of specific individual mutations found in Omicron. To date, sotrovimab has demonstrated ongoing activity against all tested variants of concern and interest defined by the World Health Organization (WHO). The companies are now completing in vitro pseudo-virus testing to confirm the neutralizing activity of sotrovimab against the combination of all the Omicron mutations with the intent to provide an update by the end of 2021.</p><p><blockquote>伦敦和三藩市，2021年12月2日（环球通讯社）--葛兰素史克公司（伦敦证券交易所/纽约证券交易所股票代码：GSK）和Vir Biotechnology，Inc.（纳斯达克股票代码：VIR）今天宣布更新预印本服务器bioRxiv，临床前数据表明sotrovimab是一种在研单克隆抗体，保留了针对新Omicron SARS-CoV-2变体(B.1.1.529)的关键突变1的活性，包括在sotrovimab结合位点中发现的突变1的活性。这些数据是通过对在奥密克戎发现的特定个体突变进行假病毒测试而产生的。迄今为止，sotrovimab已显示出针对世界卫生组织(WHO)定义的所有受关注和感兴趣的测试变体的持续活性。两家公司目前正在完成体外假病毒测试，以确认sotrovimab对所有奥密克戎突变组合的中和活性，并打算在2021年底前提供更新。</blockquote></p><p> <b>George Scangos, Ph.D., Chief Executive Officer of Vir, said:</b>“Sotrovimab was deliberately designed with a mutating virus in mind. By targeting a highly conserved region of the spike protein that is less likely to mutate, we hoped to address both the current SARS-CoV-2 virus and future variants that we expected would be inevitable. This hypothesis has borne out again and again – with its ongoing ability to maintain activity against all tested variants of concern and interest to date, including key mutations found in Omicron, as demonstrated by pre-clinical data. We have every expectation that this positive trend will continue and are working rapidly to confirm its activity against the full combination sequence of Omicron.”</p><p><blockquote><b>Vir首席执行官George Scangos博士表示：</b>“Sotrovimab在设计时考虑到了一种突变病毒。通过靶向刺突蛋白中不太可能突变的高度保守区域，我们希望解决当前的新型冠状病毒病毒和我们预计不可避免的未来变种。这一假设已经一次又一次地得到证实——正如临床前数据所证明的那样，它能够持续保持针对迄今为止所有受关注和感兴趣的测试变种的活性，包括在奥密克戎发现的关键突变。我们完全预计这种积极趋势将持续下去，并正在迅速努力确认其针对奥密克戎全组合序列的活性。”</blockquote></p><p> <b>Dr.Hal Barron, Chief Scientific Officer and President R&amp;D, GSK, said:</b>“Since the beginning of the pandemic, we have been working with Vir to combine our scientific expertise and technologies to deliver an enduring treatment option for patients with COVID-19. Though early, these pre-clinical data support our long-held view on the potential for sotrovimab to maintain its activity as the virus continues to mutate. We are pleased that this treatment option is available to patients in the US and many other countries, and are working to expand access worldwide.”</p><p><blockquote><b>葛兰素史克首席科学官兼研发总裁Hal Barron博士表示：</b>“自大流行开始以来，我们一直与Vir合作，结合我们的科学专业知识和技术，为COVID-19患者提供持久的治疗选择。虽然还为时过早，但这些临床前数据支持了我们长期以来对随着病毒不断变异，sotrovimab有可能维持其活性。我们很高兴美国和许多其他国家的患者可以使用这种治疗方案，并正在努力扩大全球范围。”</blockquote></p><p> <b>About Sotrovimab</b>Sotrovimab is an investigational SARS-CoV-2 neutralizing monoclonal antibody. The antibody binds to an epitope on SARS-CoV-2 shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop. Sotrovimab, which incorporates Xencor’s Xtend™ technology, has also been designed to achieve high concentration in the lungs to ensure optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life.</p><p><blockquote><b>关于Sotrovimab</b>Sotrovimab是一种在研新型冠状病毒中和单克隆抗体。该抗体与新型冠状病毒上与SARS-CoV-1（导致SARS的病毒）共有的表位结合，表明该表位高度保守，这可能会使耐药性更难产生。Sotrovimab，结合了Xencor的Xtend™技术，也被设计成在肺中实现高浓度，以确保最佳渗透到受新型冠状病毒病影响的气道组织中，并具有延长的半衰期。</blockquote></p><p> Updated in vitro data, published in&nbsp;<i>bioRxiv</i>, demonstrate that sotrovimab retains activity against all current tested variants of concern and interest of the SARS-CoV-2 virus as defined by WHO, plus others, including but not limited to Delta (B.1.617.2), Delta Plus (AY.1 or AY.2), Mu (B.1.621) and key mutations of Omicron (B.1.1.529).</p><p><blockquote>更新的体外数据，发表于<i>bioRxiv</i>，证明sotrovimab对世卫组织定义的所有当前测试的关注和感兴趣的新型冠状病毒病毒变体以及其他变体保持活性，包括但不限于Delta（B.1.617.2）、Delta Plus（AY.1或AY.2）、Mu（B.1.621）和奥密克戎的关键突变（B.1.1.529）。</blockquote></p><p> <b>About the sotrovimab clinical development program</b></p><p><blockquote><b>关于sotrovimab临床开发项目</b></blockquote></p><p></p><p> <ul>  <li>COMET-ICE: a Phase 3, multi-center, double-blind, placebo-controlled trial investigated an intravenous (IV) infusion of sotrovimab in adults with mild-to-moderate COVID-19 at high risk of progression to severe disease, who are not hospitalized and not requiring oxygen. The final COMET-ICE trial results in the full trial population of 1,057 participants demonstrated a 79% reduction (adjusted relative risk reduction) (p&lt;0.001) in hospitalization for more than 24 hours or death due to any cause by Day 29 compared to placebo, meeting the primary endpoint of the trial. Interim data were published in<i><u>The New England Journal of Medicine</u></i>on October 27, 2021 and final data were pre-published on November 8, 2021 on<i><u>medRxiv</u></i>.</li>  <li>COMET-TAIL: a Phase 3, randomized, multi-center, open-label, non-inferiority trial of intramuscular (IM) versus IV administration of sotrovimab for the early treatment of mild-to-moderate COVID-19 in high-risk non-hospitalized adult and pediatric patients (12 years of age and older). The trial’s primary endpoint was met, and headline data demonstrated that intramuscularly administered sotrovimab was non-inferior and offered similar efficacy to intravenous administration for high-risk populations. The companies plan to submit the complete COMET-TAIL data set to a peer-reviewed&nbsp;journal for publication in the first quarter of 2022.</li>  <li>COMET-PEAK: a Phase 2, randomized, multi-center, parallel-group trial evaluating IV and IM administration of sotrovimab in outpatients with mild-to-moderate COVID-19. Data available to date from open-label Part B of the trial (500mg IV vs. 500mg IM) demonstrated equivalence on the virological response between the IM and IV arms. The companies plan to submit the complete COMET-PEAK data set to a peer-reviewed journal for publication in due course.</li>  <li>GSK and Vir are also partnering to investigate the use of sotrovimab in uninfected immunocompromised adults to determine whether sotrovimab can prevent symptomatic COVID-19 infection. GSK and Vir are supporting investigator-sponsored studies and fostering scientific collaborations with experienced investigators and networks involved in the continuum of care of immunocompromised patients, to understand the role sotrovimab for prophylaxis could play in this population. Discussions with regulatory authorities regarding the prophylaxis program will take place in due course.</li> </ul> <b>About global access to sotrovimab</b></p><p><blockquote><ul><li>COMET-ICE：一项3期、多中心、双盲、安慰剂对照试验研究了在进展为严重疾病的高风险、未住院且不需要氧气的轻中度新冠肺炎成人中静脉（IV）输注sotrovimab。在1,057名参与者的完整试验人群中，最终COMET-ICE试验结果显示，与安慰剂相比，第29天住院超过24小时或因任何原因死亡的人数减少了79%（调整后的相对风险降低）（p&lt;0.001），达到了试验的主要终点。中期数据发表于<i><u>新英格兰医学杂志</u></i>2021年10月27日，最终数据于2021年11月8日预发布<i><u>medRxiv</u></i>.</li><li>COMET-TAIL：一项3期、随机、多中心、开放标签、非劣效性试验，在高危非住院成人和儿童患者（12岁及以上）中，肌肉注射（IM）与静脉注射sotrovimab用于早期治疗轻度至中度新冠肺炎。该试验的主要终点达到了，主要数据表明，对于高危人群，肌肉注射sotrovimab并不劣效，并且提供了与静脉注射相似的疗效。两家公司计划将完整的彗尾数据集提交给同行评审期刊，以便于2022年第一季度发表。</li><li>COMET-PEAK：一项2期、随机、多中心、平行组试验，评估轻度至中度新冠肺炎门诊患者静脉注射和肌肉注射sotrovimab。迄今为止，来自试验开放标签B部分的可用数据（500mg IV vs.500mg IM）证明了IM组和IV组之间的病毒学应答等效。两家公司计划将完整的彗星峰值数据集提交给同行评审期刊，以便在适当的时候发表。</li><li>GSK和Vir还合作研究sotrovimab在未感染的免疫功能低下成人中的使用情况，以确定sotrovimab是否可以预防有症状的新冠肺炎感染。GSK和Vir正在支持研究者赞助的研究，并促进与参与免疫功能低下患者连续护理的经验丰富的研究者和网络的科学合作，以了解sotrovimab在该人群中的预防作用。将在适当的时候与监管机构讨论预防计划。</li></ul><b>关于sotrovimab的全球准入</b></blockquote></p><p> <ul>  <li>Sotrovimab is authorized for emergency use in the United States. Xevudy (sotrovimab) received apositive scientific opinionunder Article 5(3) of Regulation 726/2004 from the Committee for Human Medicinal Products (CHMP) in the EU, has been granted a provisional marketing authorization in Australia, and conditional marketing authorization in Saudi Arabia. In Japan, it has been approved via the Special Approval for Emergency Pathway. Temporary authorizations for sotrovimab have been granted in a dozen countries.</li>  <li>GSK and Vir also recently submitted the Marketing Authorization Application (MAA) to the European Medicines Agency for Xevudy (sotrovimab) for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (COVID-19) who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19.</li>  <li>Sotrovimab is supplied in several countries worldwide, including through national agreements in the United States, United Kingdom, Japan, Australia, Canada, Singapore, Switzerland and United Arab Emirates. We have also signed a Joint Procurement Agreement with the European Commission to supply doses of sotrovimab. Additional agreements are yet to be announced due to confidentiality or regulatory requirements.</li> </ul> <b>Sotrovimab in the United States</b>The following is a summary of information for sotrovimab. Healthcare providers in the U.S. should review the Fact Sheets for information about the authorized use of sotrovimab and mandatory requirements of the EUA. Please see the<u>Food and Drug Administration (FDA) Letter of Authorization</u>, full<u>Fact Sheet for Healthcare Providers</u>and full<u>Fact Sheet for Patients, Parents, and Caregivers</u>.</p><p><blockquote><ul><li>Sotrovimab在美国被授权紧急使用。Xevudy(sotrovimab)根据欧盟人类药品委员会(CHMP)第726/2004号法规第5(3)条获得了积极的科学意见，已在澳大利亚获得临时营销授权，在沙特阿拉伯获得有条件营销授权。在日本，它已通过紧急途径的特别批准获得批准。sotrovimab已在十几个国家获得临时授权。</li><li>GSK和Vir最近还向欧洲药品管理局提交了Xevudy（sotrovimab）的上市许可申请（MAA），用于治疗不需要补充氧气且有进展为严重新冠肺炎风险的2019冠状病毒病（COVID-19）成人和青少年（12岁及以上，体重至少40公斤）。</li><li>Sotrovimab在全球多个国家供应，包括通过美国、英国、日本、澳大利亚、加拿大、新加坡、瑞士和阿拉伯联合酋长国的国家协议。我们还与欧盟委员会签署了一项联合采购协议，以供应sotrovimab的剂量。由于保密或监管要求，其他协议尚未公布。</li></ul><b>Sotrovimab在美国</b>以下是sotrovimab的信息总结。美国的医疗保健提供者应查看情况说明书，了解有关sotrovimab授权使用和EUA强制性要求的信息。请参阅<u>食品药品监督管理局（FDA）授权书</u>，满的<u>医疗保健提供者概况介绍</u>和满的<u>给患者、父母和护理人员的情况说明书</u>.</blockquote></p><p> Sotrovimab&nbsp;has been authorized by the US FDA for the emergency use described below. Sotrovimab&nbsp;is not FDA-approved for this use.</p><p><blockquote>Sotrovimab已获得美国FDA的紧急使用授权，如下所述。Sotrovimab未被FDA批准用于此用途。</blockquote></p><p> Sotrovimab&nbsp;is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of&nbsp;sotrovimab&nbsp;under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.</p><p><blockquote>Sotrovimab仅在根据法案第564（b）（1）节，21 U.S.C.360BBB-3（b）（1）宣布存在证明授权紧急使用Sotrovimab的情况期间获得授权，除非授权提前终止或撤销。</blockquote></p><p></p><p> <b>Authorized Use</b>The U.S. FDA has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product sotrovimab for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12&nbsp;years of age and older weighing at least 40&nbsp;kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.</p><p><blockquote><b>授权使用</b>美国FDA已发布紧急使用授权（EUA），允许紧急使用未经批准的产品sotrovimab，用于治疗成人和儿科患者（12岁及以上，体重至少40公斤）的轻中度冠状病毒疾病2019（COVID-19），这些患者直接新型冠状病毒病毒检测结果呈阳性，并且有进展为严重COVID-19（包括住院或死亡）的高风险。</blockquote></p><p> <b>Limitations of Authorized Use</b>Sotrovimab is not authorized for use in patients:</p><p><blockquote><b>授权使用的限制</b>Sotrovimab未被授权用于以下患者：</blockquote></p><p> <ul>  <li>who are hospitalized due to COVID-19, OR</li>  <li>who require oxygen therapy due to COVID-19, OR</li>  <li>who require an increase in baseline oxygen flow rate due to COVID-19 (in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity)</li> </ul> Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID‑19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID‑19 requiring high flow oxygen or mechanical ventilation.</p><p><blockquote><ul><li>因COVID-19住院的人，或</li><li>因COVID-19需要氧疗的人，或</li><li>因新冠肺炎而需要增加基线氧流量的人（因潜在的非新冠肺炎相关合并症而接受慢性氧疗的人）</li></ul>在因COVID-19住院的患者中未观察到sotrovimab治疗的益处。当给予需要高流量氧气或机械通气的COVID-19住院患者时，新型冠状病毒单克隆抗体可能与更差的临床结局相关。</blockquote></p><p> <b>Important Safety Information</b></p><p><blockquote><b>重要安全信息</b></blockquote></p><p> <b>CONTRAINDICATIONS</b></p><p><blockquote><b>禁忌证</b></blockquote></p><p> Sotrovimab is contraindicated in patients who have a history of anaphylaxis to sotrovimab or to any of the excipients in the formulation.</p><p><blockquote>对sotrovimab或制剂中的任何赋形剂有过敏反应史的患者禁用sotrovimab。</blockquote></p><p> <b>WARNINGS AND PRECAUTIONS</b></p><p><blockquote><b>警告和注意事项</b></blockquote></p><p> There are limited clinical data available for sotrovimab. Serious and unexpected adverse events may occur that have not been previously reported with sotrovimab use.</p><p><blockquote>sotrovimab的可用临床数据有限。使用sotrovimab可能会发生以前未报告的严重和意外不良事件。</blockquote></p><p> <b>Hypersensitivity Including Anaphylaxis and Infusion-Related Reactions</b></p><p><blockquote><b>超敏反应，包括过敏反应和输液相关反应</b></blockquote></p><p> Serious hypersensitivity reactions, including anaphylaxis, have been observed with administration of sotrovimab. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive care.</p><p><blockquote>服用sotrovimab后观察到严重的超敏反应，包括过敏反应。如果出现临床上显著的超敏反应或过敏反应的体征和症状，立即停止给药并开始适当的药物和/或支持性护理。</blockquote></p><p> Infusion-related reactions, occurring during the infusion and up to 24 hours after the infusion, have been observed with administration of sotrovimab. These reactions may be severe or life threatening.</p><p><blockquote>服用sotrovimab时观察到输注期间和输注后24小时内发生的输注相关反应。这些反应可能很严重或危及生命。</blockquote></p><p> Signs and symptoms of infusion-related reactions may include: fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (eg, atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, vaso-vagal reactions (eg, pre-syncope, syncope), dizziness and diaphoresis.</p><p><blockquote>输注相关反应的体征和症状可能包括：发热、呼吸困难、氧饱和度降低、寒战、疲劳、心律失常（如房颤、窦性心动过速、心动过缓）、胸痛或不适、虚弱、精神状态改变、恶心、头痛、支气管痉挛、低血压、高血压、血管水肿、咽喉刺激、皮疹（包括荨麻疹）、瘙痒、肌痛、血管迷走神经反应（如晕厥前、晕厥）、头晕和出汗。</blockquote></p><p> Consider slowing or stopping the infusion and administer appropriate medications and/or supportive care if an infusion-related reaction occurs.</p><p><blockquote>如果发生输注相关反应，考虑减慢或停止输注，并给予适当的药物和/或支持性护理。</blockquote></p><p> Hypersensitivity reactions occurring more than 24 hours after the infusion have also been reported with the use of SARS-CoV-2 monoclonal antibodies under Emergency Use Authorization.</p><p><blockquote>在紧急使用授权下使用新型冠状病毒单克隆抗体时，也报告了输注后超过24小时发生的超敏反应。</blockquote></p><p> <b>Clinical Worsening After SARS-CoV-2 Monoclonal Antibody Administration</b></p><p><blockquote><b>新型冠状病毒单克隆抗体给药后临床恶化</b></blockquote></p><p> Clinical worsening of COVID‑19 after administration of SARS-CoV-2 monoclonal antibody treatment has been reported and may include signs or symptoms of fever, hypoxia or increased respiratory difficulty, arrhythmia (eg, atrial fibrillation, tachycardia, bradycardia), fatigue and altered mental status. Some of these events required hospitalization. It is not known if these events were related to SARS-CoV-2 monoclonal antibody use or were due to progression of COVID‑19.</p><p><blockquote>据报道，接受新型冠状病毒单克隆抗体治疗后，COVID-19的临床恶化可能包括发热、缺氧或呼吸困难增加、心律失常（如房颤、心动过速、心动过缓）、疲劳和精神状态改变的体征或症状。其中一些事件需要住院治疗。尚不清楚这些事件是与新型冠状病毒单克隆抗体的使用有关，还是由于COVID-19的进展。</blockquote></p><p> <b>Limitations of Benefit and Potential for Risk in Patients with Severe COVID‑19</b></p><p><blockquote><b>重症COVID-19患者的获益限制和潜在风险</b></blockquote></p><p> Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID‑19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID‑19 requiring high flow oxygen or mechanical ventilation. Therefore, sotrovimab is not authorized for use in patients: who are hospitalized due to COVID‑19, OR who require oxygen therapy due to COVID‑19 OR who require an increase in baseline oxygen flow rate due to COVID‑19 in those on chronic oxygen therapy due to underlying non‑COVID‑19 related comorbidity.</p><p><blockquote>在因COVID-19住院的患者中未观察到sotrovimab治疗的益处。当给予需要高流量氧气或机械通气的COVID-19住院患者时，新型冠状病毒单克隆抗体可能与更差的临床结局相关。因此，sotrovimab未被授权用于以下患者：因COVID-19住院的患者，或因COVID-19需要氧疗的患者，或因COVID-19需要增加基线氧流量的患者，以及因潜在的非COVID-19相关合并症而接受慢性氧疗的患者。</blockquote></p><p> <b>ADVERSE EVENTS</b></p><p><blockquote><b>不良事件</b></blockquote></p><p> Hypersensitivity adverse reactions have been observed in 2% of patients treated with sotrovimab and 1% with placebo in COMET-ICE.</p><p><blockquote>在COMET-ICE中，在2%接受sotrovimab治疗的患者和1%接受安慰剂治疗的患者中观察到超敏反应。</blockquote></p><p> The most common treatment-emergent adverse events observed in the sotrovimab treatment group in COMET-ICE were rash (1%) and diarrhea (2%), all of which were Grade 1 (mild) or Grade 2 (moderate). No other treatment-emergent adverse events were reported at a higher rate with sotrovimab compared to placebo.</p><p><blockquote>COMET-ICE中sotrovimab治疗组观察到的最常见的治疗后出现的不良事件为皮疹（1%）和腹泻（2%），均为1级（轻度）或2级（中度）。与安慰剂相比，sotrovimab组未报告其他治疗中出现的不良事件发生率更高。</blockquote></p><p> <b>USE IN SPECIFIC POPULATIONS</b></p><p><blockquote><b>用于特定人群</b></blockquote></p><p> <b>Pregnancy</b></p><p><blockquote><b>妊娠</b></blockquote></p><p></p><p> There are insufficient data to evaluate a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcome. Sotrovimab should be used during pregnancy only if the potential benefit justifies the potential risk for the mother and the fetus.</p><p><blockquote>没有足够的数据来评估药物相关的重大出生缺陷、流产或不良母体或胎儿结局的风险。只有当潜在益处证明对母亲和胎儿的潜在风险合理时，才应在妊娠期间使用Sotrovimab。</blockquote></p><p> <b>Lactation</b></p><p><blockquote><b>哺乳期</b></blockquote></p><p> There are no available data on the presence of sotrovimab in human milk, the effects on the breastfed infant or the effects on milk production. Individuals with COVID-19 who are breastfeeding should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.</p><p><blockquote>没有关于母乳中sotrovimab的存在、对母乳喂养婴儿的影响或对产奶量的影响的可用数据。正在母乳喂养的新冠肺炎患者应遵循临床指南的做法，以避免婴儿接触新冠肺炎。</blockquote></p><p> <b>About theVir andGSKCollaboration</b>In April 2020, Vir and GSK entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration uses Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventive options to help address the current COVID-19 pandemic and future outbreaks. The companies will leverage GSK’s expertise in functional genomics and combine their capabilities in CRISPR screening and artificial intelligence to identify anti-coronavirus compounds that target cellular host genes. They will also apply their combined expertise to research SARS-CoV-2 and other coronavirus vaccines.</p><p><blockquote><b>关于theVir和GSK合作</b>2020年4月，Vir和GSK达成合作，研究和开发冠状病毒的解决方案，包括导致COVID-19的新型冠状病毒病毒。此次合作使用Vir专有的单克隆抗体平台技术来加速现有的和识别新的抗病毒抗体，这些抗体可用作治疗或预防选择，以帮助应对当前的新冠肺炎疫情和未来的疫情。两家公司将利用GSK在功能基因组学方面的专业知识，并结合其在CRISPR筛选和人工智能方面的能力，以识别靶向细胞宿主基因的抗冠状病毒化合物。他们还将运用他们的综合专业知识来研究新型冠状病毒和其他冠状病毒疫苗。</blockquote></p><p> <b>GSKCommitment toTackling COVID-19</b></p><p><blockquote><b>GSK致力于应对COVID-19</b></blockquote></p><p> GSK’s response to COVID-19 has been one of the broadest in the industry, with potential treatments in addition to our vaccine candidates in development with partner organizations.</p><p><blockquote>葛兰素史克对COVID-19的反应是业内最广泛的反应之一，除了我们与合作伙伴组织正在开发的候选疫苗之外，还提供了潜在的治疗方法。</blockquote></p><p> GSK is collaborating with several organizations on COVID-19 vaccines by providing access to our adjuvant technology. We are working with Sanofi SA, Medicago Inc. and SK bioscience Co., Ltd. to&nbsp;develop&nbsp;adjuvanted, protein-based vaccine candidates, and&nbsp;all&nbsp;are&nbsp;now in Phase&nbsp;3&nbsp;clinical trials. The use of an adjuvant can be of particular importance in a pandemic since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and contributing to protecting more people in need.</p><p><blockquote>葛兰素史克正在与多个组织合作开发新冠肺炎疫苗，提供我们的佐剂技术。我们正在与Sanofi SA、Medicago Inc.和SK bioscience Co., Ltd.合作开发基于佐剂的蛋白质候选疫苗，目前均处于3期临床试验。佐剂的使用在大流行中可能特别重要，因为它可以减少每剂所需的疫苗蛋白的量，允许生产更多的疫苗剂量并有助于保护更多有需要的人。</blockquote></p><p> GSK is also working with mRNA specialist, CureVac NV, to jointly develop next-generation, optimized mRNA vaccines for COVID-19 with the potential to address multiple emerging variants in one vaccine.</p><p><blockquote>葛兰素史克还与mRNA专家CureVac NV合作，共同开发下一代优化的新冠肺炎mRNA疫苗，有可能在一种疫苗中解决多种新出现的变异。</blockquote></p><p> GSK is also exploring treatments for COVID-19 patients, collaborating with Vir Biotechnology to investigate monoclonal antibodies that could be used as therapeutic or preventive options for COVID-19.</p><p><blockquote>葛兰素史克还在探索新冠肺炎患者的治疗方法，与Vir Biotechnology合作研究可用作新冠肺炎治疗或预防选择的单克隆抗体。</blockquote></p><p> <b>Vir’sCommitment to COVID-19</b>Vir was founded with the mission of addressing the world’s most serious infectious diseases. In 2020, Vir responded rapidly to the COVID-19 pandemic by leveraging our unique scientific insights and industry-leading antibody platform to explore multiple monoclonal antibodies as potential therapeutic or preventive options for COVID-19. Sotrovimab is the first SARS-CoV-2-targeting antibody Vir advanced into the clinic. It was carefully selected for its demonstrated promise in preclinical research, including an anticipated high barrier to resistance and potential ability to both block the virus from entering healthy cells and clear infected cells. Vir is continuing to pursue novel therapeutic and prophylactic solutions to combat SARS-CoV-2 and future coronavirus pandemics, both independently and in collaboration with its partners.</p><p><blockquote><b>Vir对COVID-19的承诺</b>Vir成立的使命是解决世界上最严重的传染病。2020年，Vir利用我们独特的科学见解和行业领先的抗体平台，探索多种单克隆抗体作为COVID-19的潜在治疗或预防选择，迅速应对COVID-19大流行。Sotrovimab是第一个挺进临床的新型冠状病毒靶向抗体Vir。它被精心选择是因为它在临床前研究中表现出的前景，包括预期的高耐药性屏障和阻止病毒进入健康细胞和清除受感染细胞的潜在能力。Vir正在继续寻求新的治疗和预防解决方案，以应对新型冠状病毒和未来的冠状病毒大流行，无论是独立还是与其合作伙伴合作。</blockquote></p><p> <b>About GSK</b></p><p><blockquote><b>关于GSK</b></blockquote></p><p> GSK is a science-led global healthcare company. For further information please visitwww.gsk.com/aboutus.</p><p><blockquote>葛兰素史克是一家以科学为主导的全球医疗保健公司。欲了解更多信息，请访问www.gsk.com/aboutus。</blockquote></p><p> <b>About Vir Biotechnology</b></p><p><blockquote><b>关于维尔生物技术</b></blockquote></p><p> Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus. For more information, please visitwww.vir.bio.</p><p><blockquote>Vir Biotechnology是一家商业阶段的免疫学公司，专注于将免疫学见解与尖端技术相结合，以治疗和预防严重的传染病。Vir组装了四个技术平台，旨在通过利用对天然免疫过程的关键观察来刺激和增强免疫系统。其目前的开发管线包括针对COVID-19、乙型肝炎病毒、甲型流感和人类免疫缺陷病毒的候选产品。欲了解更多信息，请访问www.vir.bio。</blockquote></p><p> <b>GSK Cautionary Statement Regarding Forward-Looking Statements</b></p><p><blockquote><b>葛兰素史克关于前瞻性陈述的警告声明</b></blockquote></p><p> GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2020, GSK’s Q3 Results and any impacts of the COVID-19 pandemic.</p><p><blockquote>葛兰素史克提醒投资者，葛兰素史克做出的任何前瞻性陈述或预测，包括本公告中做出的陈述或预测，都受到风险和不确定性的影响，可能导致实际结果与预测结果存在重大差异。这些因素包括但不限于公司2020年20-F表格年度报告中描述的因素、葛兰素史克第三季度业绩以及COVID-19大流行的任何影响。</blockquote></p><p></p><p> <b>Vir Forward-Looking Statements</b>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “plan,” “potential,” “aim,” “promising” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Vir’s expectations and assumptions as of the date of this press release. Forward-looking statements contained in this press release include, but are not limited to, statements regarding the ability of sotrovimab to treat and/or prevent COVID-19 either through IV or IM administration, Vir’s collaboration with GSK, plans to progress regulatory submissions globally, including with the FDA regarding the existing EUA for sotrovimab, planned discussions with other global regulatory agencies, the timing of availability of clinical data, program updates and data disclosures, the clinical development program for sotrovimab, and the ability of sotrovimab to maintain activity against circulating variants of concern and interest, including key mutations of Omicron. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, challenges in the treatment of hospitalized patients, difficulties in collaborating with other companies or government agencies, challenges in accessing manufacturing capacity, successful development and/or commercialization of alternative product candidates by Vir’s competitors, changes in expected or existing competition, delays in or disruptions to Vir’s business or clinical trials due to the COVID-19 pandemic, geopolitical changes or other external factors, and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Vir’s filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as required by law, Vir assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.</p><p><blockquote><b>Vir前瞻性陈述</b>本新闻稿包含1995年《私人证券诉讼改革法案》含义内的前瞻性陈述。诸如“可能”、“将”、“计划”、“潜力”、“目标”、“承诺”和类似表达（以及提及未来事件、条件或情况的其他词语或表达）旨在识别前瞻性陈述。这些前瞻性陈述基于Vir截至本新闻稿发布之日的预期和假设。本新闻稿中包含的前瞻性声明包括但不限于有关sotrovimab通过静脉注射或肌肉注射治疗和/或预防COVID-19的能力、Vir与GSK的合作、在全球范围内推进监管提交的计划，包括与FDA就sotrovimab现有EUA进行的计划讨论、临床数据可用性、计划更新和数据披露的时间、sotrovimab的临床开发计划以及sotrovimab维持针对令人担忧和感兴趣的循环变异体（包括奥密克戎病的关键突变）的活性的能力。许多因素可能导致当前预期和实际结果之间的差异，包括在临床前或临床研究期间观察到的意外安全性或疗效数据、住院患者治疗中的挑战、与其他公司或政府机构合作的困难、获得制造能力的挑战、Vir的竞争对手成功开发和/或商业化替代候选产品、预期或现有竞争的变化、由于COVID-19大流行、地缘政治变化或其他外部因素导致Vir的业务或临床试验延迟或中断，以及意外的诉讼或其他纠纷。Vir向美国证券交易委员会提交的文件中讨论了可能导致实际结果与本新闻稿中前瞻性陈述中明示或暗示的结果不同的其他因素，包括其中包含的标题为“风险因素”的部分。除非法律要求，Vir不承担更新此处包含的任何前瞻性陈述以反映预期的任何变化的义务，即使有新信息可用。</blockquote></p><p></p>","source":"lsy1573717531661","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Variant<blockquote>临床前数据表明Sotrovimab保留了针对关键奥密克戎突变、新新型冠状病毒变种的活性</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPreclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Variant<blockquote>临床前数据表明Sotrovimab保留了针对关键奥密克戎突变、新新型冠状病毒变种的活性</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">GlobeNewswire</strong><span class=\"h-time small\">2021-12-02 15:11</span>\n</p>\n</h4>\n</header>\n<article>\n<p>LONDON and SAN FRANCISCO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced an update tobioRxiv, a preprint server, with preclinical data demonstrating that sotrovimab, an investigational monoclonal antibody, retains activity against key mutations1of the new Omicron SARS-CoV-2 variant (B.1.1.529), including those found in the binding site of sotrovimab. These data were generated through pseudo-virus testing of specific individual mutations found in Omicron. To date, sotrovimab has demonstrated ongoing activity against all tested variants of concern and interest defined by the World Health Organization (WHO). The companies are now completing in vitro pseudo-virus testing to confirm the neutralizing activity of sotrovimab against the combination of all the Omicron mutations with the intent to provide an update by the end of 2021.</p><p><blockquote>伦敦和三藩市，2021年12月2日（环球通讯社）--葛兰素史克公司（伦敦证券交易所/纽约证券交易所股票代码：GSK）和Vir Biotechnology，Inc.（纳斯达克股票代码：VIR）今天宣布更新预印本服务器bioRxiv，临床前数据表明sotrovimab是一种在研单克隆抗体，保留了针对新Omicron SARS-CoV-2变体(B.1.1.529)的关键突变1的活性，包括在sotrovimab结合位点中发现的突变1的活性。这些数据是通过对在奥密克戎发现的特定个体突变进行假病毒测试而产生的。迄今为止，sotrovimab已显示出针对世界卫生组织(WHO)定义的所有受关注和感兴趣的测试变体的持续活性。两家公司目前正在完成体外假病毒测试，以确认sotrovimab对所有奥密克戎突变组合的中和活性，并打算在2021年底前提供更新。</blockquote></p><p> <b>George Scangos, Ph.D., Chief Executive Officer of Vir, said:</b>“Sotrovimab was deliberately designed with a mutating virus in mind. By targeting a highly conserved region of the spike protein that is less likely to mutate, we hoped to address both the current SARS-CoV-2 virus and future variants that we expected would be inevitable. This hypothesis has borne out again and again – with its ongoing ability to maintain activity against all tested variants of concern and interest to date, including key mutations found in Omicron, as demonstrated by pre-clinical data. We have every expectation that this positive trend will continue and are working rapidly to confirm its activity against the full combination sequence of Omicron.”</p><p><blockquote><b>Vir首席执行官George Scangos博士表示：</b>“Sotrovimab在设计时考虑到了一种突变病毒。通过靶向刺突蛋白中不太可能突变的高度保守区域，我们希望解决当前的新型冠状病毒病毒和我们预计不可避免的未来变种。这一假设已经一次又一次地得到证实——正如临床前数据所证明的那样，它能够持续保持针对迄今为止所有受关注和感兴趣的测试变种的活性，包括在奥密克戎发现的关键突变。我们完全预计这种积极趋势将持续下去，并正在迅速努力确认其针对奥密克戎全组合序列的活性。”</blockquote></p><p> <b>Dr.Hal Barron, Chief Scientific Officer and President R&amp;D, GSK, said:</b>“Since the beginning of the pandemic, we have been working with Vir to combine our scientific expertise and technologies to deliver an enduring treatment option for patients with COVID-19. Though early, these pre-clinical data support our long-held view on the potential for sotrovimab to maintain its activity as the virus continues to mutate. We are pleased that this treatment option is available to patients in the US and many other countries, and are working to expand access worldwide.”</p><p><blockquote><b>葛兰素史克首席科学官兼研发总裁Hal Barron博士表示：</b>“自大流行开始以来，我们一直与Vir合作，结合我们的科学专业知识和技术，为COVID-19患者提供持久的治疗选择。虽然还为时过早，但这些临床前数据支持了我们长期以来对随着病毒不断变异，sotrovimab有可能维持其活性。我们很高兴美国和许多其他国家的患者可以使用这种治疗方案，并正在努力扩大全球范围。”</blockquote></p><p> <b>About Sotrovimab</b>Sotrovimab is an investigational SARS-CoV-2 neutralizing monoclonal antibody. The antibody binds to an epitope on SARS-CoV-2 shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop. Sotrovimab, which incorporates Xencor’s Xtend™ technology, has also been designed to achieve high concentration in the lungs to ensure optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life.</p><p><blockquote><b>关于Sotrovimab</b>Sotrovimab是一种在研新型冠状病毒中和单克隆抗体。该抗体与新型冠状病毒上与SARS-CoV-1（导致SARS的病毒）共有的表位结合，表明该表位高度保守，这可能会使耐药性更难产生。Sotrovimab，结合了Xencor的Xtend™技术，也被设计成在肺中实现高浓度，以确保最佳渗透到受新型冠状病毒病影响的气道组织中，并具有延长的半衰期。</blockquote></p><p> Updated in vitro data, published in&nbsp;<i>bioRxiv</i>, demonstrate that sotrovimab retains activity against all current tested variants of concern and interest of the SARS-CoV-2 virus as defined by WHO, plus others, including but not limited to Delta (B.1.617.2), Delta Plus (AY.1 or AY.2), Mu (B.1.621) and key mutations of Omicron (B.1.1.529).</p><p><blockquote>更新的体外数据，发表于<i>bioRxiv</i>，证明sotrovimab对世卫组织定义的所有当前测试的关注和感兴趣的新型冠状病毒病毒变体以及其他变体保持活性，包括但不限于Delta（B.1.617.2）、Delta Plus（AY.1或AY.2）、Mu（B.1.621）和奥密克戎的关键突变（B.1.1.529）。</blockquote></p><p> <b>About the sotrovimab clinical development program</b></p><p><blockquote><b>关于sotrovimab临床开发项目</b></blockquote></p><p></p><p> <ul>  <li>COMET-ICE: a Phase 3, multi-center, double-blind, placebo-controlled trial investigated an intravenous (IV) infusion of sotrovimab in adults with mild-to-moderate COVID-19 at high risk of progression to severe disease, who are not hospitalized and not requiring oxygen. The final COMET-ICE trial results in the full trial population of 1,057 participants demonstrated a 79% reduction (adjusted relative risk reduction) (p&lt;0.001) in hospitalization for more than 24 hours or death due to any cause by Day 29 compared to placebo, meeting the primary endpoint of the trial. Interim data were published in<i><u>The New England Journal of Medicine</u></i>on October 27, 2021 and final data were pre-published on November 8, 2021 on<i><u>medRxiv</u></i>.</li>  <li>COMET-TAIL: a Phase 3, randomized, multi-center, open-label, non-inferiority trial of intramuscular (IM) versus IV administration of sotrovimab for the early treatment of mild-to-moderate COVID-19 in high-risk non-hospitalized adult and pediatric patients (12 years of age and older). The trial’s primary endpoint was met, and headline data demonstrated that intramuscularly administered sotrovimab was non-inferior and offered similar efficacy to intravenous administration for high-risk populations. The companies plan to submit the complete COMET-TAIL data set to a peer-reviewed&nbsp;journal for publication in the first quarter of 2022.</li>  <li>COMET-PEAK: a Phase 2, randomized, multi-center, parallel-group trial evaluating IV and IM administration of sotrovimab in outpatients with mild-to-moderate COVID-19. Data available to date from open-label Part B of the trial (500mg IV vs. 500mg IM) demonstrated equivalence on the virological response between the IM and IV arms. The companies plan to submit the complete COMET-PEAK data set to a peer-reviewed journal for publication in due course.</li>  <li>GSK and Vir are also partnering to investigate the use of sotrovimab in uninfected immunocompromised adults to determine whether sotrovimab can prevent symptomatic COVID-19 infection. GSK and Vir are supporting investigator-sponsored studies and fostering scientific collaborations with experienced investigators and networks involved in the continuum of care of immunocompromised patients, to understand the role sotrovimab for prophylaxis could play in this population. Discussions with regulatory authorities regarding the prophylaxis program will take place in due course.</li> </ul> <b>About global access to sotrovimab</b></p><p><blockquote><ul><li>COMET-ICE：一项3期、多中心、双盲、安慰剂对照试验研究了在进展为严重疾病的高风险、未住院且不需要氧气的轻中度新冠肺炎成人中静脉（IV）输注sotrovimab。在1,057名参与者的完整试验人群中，最终COMET-ICE试验结果显示，与安慰剂相比，第29天住院超过24小时或因任何原因死亡的人数减少了79%（调整后的相对风险降低）（p&lt;0.001），达到了试验的主要终点。中期数据发表于<i><u>新英格兰医学杂志</u></i>2021年10月27日，最终数据于2021年11月8日预发布<i><u>medRxiv</u></i>.</li><li>COMET-TAIL：一项3期、随机、多中心、开放标签、非劣效性试验，在高危非住院成人和儿童患者（12岁及以上）中，肌肉注射（IM）与静脉注射sotrovimab用于早期治疗轻度至中度新冠肺炎。该试验的主要终点达到了，主要数据表明，对于高危人群，肌肉注射sotrovimab并不劣效，并且提供了与静脉注射相似的疗效。两家公司计划将完整的彗尾数据集提交给同行评审期刊，以便于2022年第一季度发表。</li><li>COMET-PEAK：一项2期、随机、多中心、平行组试验，评估轻度至中度新冠肺炎门诊患者静脉注射和肌肉注射sotrovimab。迄今为止，来自试验开放标签B部分的可用数据（500mg IV vs.500mg IM）证明了IM组和IV组之间的病毒学应答等效。两家公司计划将完整的彗星峰值数据集提交给同行评审期刊，以便在适当的时候发表。</li><li>GSK和Vir还合作研究sotrovimab在未感染的免疫功能低下成人中的使用情况，以确定sotrovimab是否可以预防有症状的新冠肺炎感染。GSK和Vir正在支持研究者赞助的研究，并促进与参与免疫功能低下患者连续护理的经验丰富的研究者和网络的科学合作，以了解sotrovimab在该人群中的预防作用。将在适当的时候与监管机构讨论预防计划。</li></ul><b>关于sotrovimab的全球准入</b></blockquote></p><p> <ul>  <li>Sotrovimab is authorized for emergency use in the United States. Xevudy (sotrovimab) received apositive scientific opinionunder Article 5(3) of Regulation 726/2004 from the Committee for Human Medicinal Products (CHMP) in the EU, has been granted a provisional marketing authorization in Australia, and conditional marketing authorization in Saudi Arabia. In Japan, it has been approved via the Special Approval for Emergency Pathway. Temporary authorizations for sotrovimab have been granted in a dozen countries.</li>  <li>GSK and Vir also recently submitted the Marketing Authorization Application (MAA) to the European Medicines Agency for Xevudy (sotrovimab) for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (COVID-19) who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19.</li>  <li>Sotrovimab is supplied in several countries worldwide, including through national agreements in the United States, United Kingdom, Japan, Australia, Canada, Singapore, Switzerland and United Arab Emirates. We have also signed a Joint Procurement Agreement with the European Commission to supply doses of sotrovimab. Additional agreements are yet to be announced due to confidentiality or regulatory requirements.</li> </ul> <b>Sotrovimab in the United States</b>The following is a summary of information for sotrovimab. Healthcare providers in the U.S. should review the Fact Sheets for information about the authorized use of sotrovimab and mandatory requirements of the EUA. Please see the<u>Food and Drug Administration (FDA) Letter of Authorization</u>, full<u>Fact Sheet for Healthcare Providers</u>and full<u>Fact Sheet for Patients, Parents, and Caregivers</u>.</p><p><blockquote><ul><li>Sotrovimab在美国被授权紧急使用。Xevudy(sotrovimab)根据欧盟人类药品委员会(CHMP)第726/2004号法规第5(3)条获得了积极的科学意见，已在澳大利亚获得临时营销授权，在沙特阿拉伯获得有条件营销授权。在日本，它已通过紧急途径的特别批准获得批准。sotrovimab已在十几个国家获得临时授权。</li><li>GSK和Vir最近还向欧洲药品管理局提交了Xevudy（sotrovimab）的上市许可申请（MAA），用于治疗不需要补充氧气且有进展为严重新冠肺炎风险的2019冠状病毒病（COVID-19）成人和青少年（12岁及以上，体重至少40公斤）。</li><li>Sotrovimab在全球多个国家供应，包括通过美国、英国、日本、澳大利亚、加拿大、新加坡、瑞士和阿拉伯联合酋长国的国家协议。我们还与欧盟委员会签署了一项联合采购协议，以供应sotrovimab的剂量。由于保密或监管要求，其他协议尚未公布。</li></ul><b>Sotrovimab在美国</b>以下是sotrovimab的信息总结。美国的医疗保健提供者应查看情况说明书，了解有关sotrovimab授权使用和EUA强制性要求的信息。请参阅<u>食品药品监督管理局（FDA）授权书</u>，满的<u>医疗保健提供者概况介绍</u>和满的<u>给患者、父母和护理人员的情况说明书</u>.</blockquote></p><p> Sotrovimab&nbsp;has been authorized by the US FDA for the emergency use described below. Sotrovimab&nbsp;is not FDA-approved for this use.</p><p><blockquote>Sotrovimab已获得美国FDA的紧急使用授权，如下所述。Sotrovimab未被FDA批准用于此用途。</blockquote></p><p> Sotrovimab&nbsp;is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of&nbsp;sotrovimab&nbsp;under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.</p><p><blockquote>Sotrovimab仅在根据法案第564（b）（1）节，21 U.S.C.360BBB-3（b）（1）宣布存在证明授权紧急使用Sotrovimab的情况期间获得授权，除非授权提前终止或撤销。</blockquote></p><p></p><p> <b>Authorized Use</b>The U.S. FDA has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product sotrovimab for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12&nbsp;years of age and older weighing at least 40&nbsp;kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.</p><p><blockquote><b>授权使用</b>美国FDA已发布紧急使用授权（EUA），允许紧急使用未经批准的产品sotrovimab，用于治疗成人和儿科患者（12岁及以上，体重至少40公斤）的轻中度冠状病毒疾病2019（COVID-19），这些患者直接新型冠状病毒病毒检测结果呈阳性，并且有进展为严重COVID-19（包括住院或死亡）的高风险。</blockquote></p><p> <b>Limitations of Authorized Use</b>Sotrovimab is not authorized for use in patients:</p><p><blockquote><b>授权使用的限制</b>Sotrovimab未被授权用于以下患者：</blockquote></p><p> <ul>  <li>who are hospitalized due to COVID-19, OR</li>  <li>who require oxygen therapy due to COVID-19, OR</li>  <li>who require an increase in baseline oxygen flow rate due to COVID-19 (in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity)</li> </ul> Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID‑19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID‑19 requiring high flow oxygen or mechanical ventilation.</p><p><blockquote><ul><li>因COVID-19住院的人，或</li><li>因COVID-19需要氧疗的人，或</li><li>因新冠肺炎而需要增加基线氧流量的人（因潜在的非新冠肺炎相关合并症而接受慢性氧疗的人）</li></ul>在因COVID-19住院的患者中未观察到sotrovimab治疗的益处。当给予需要高流量氧气或机械通气的COVID-19住院患者时，新型冠状病毒单克隆抗体可能与更差的临床结局相关。</blockquote></p><p> <b>Important Safety Information</b></p><p><blockquote><b>重要安全信息</b></blockquote></p><p> <b>CONTRAINDICATIONS</b></p><p><blockquote><b>禁忌证</b></blockquote></p><p> Sotrovimab is contraindicated in patients who have a history of anaphylaxis to sotrovimab or to any of the excipients in the formulation.</p><p><blockquote>对sotrovimab或制剂中的任何赋形剂有过敏反应史的患者禁用sotrovimab。</blockquote></p><p> <b>WARNINGS AND PRECAUTIONS</b></p><p><blockquote><b>警告和注意事项</b></blockquote></p><p> There are limited clinical data available for sotrovimab. Serious and unexpected adverse events may occur that have not been previously reported with sotrovimab use.</p><p><blockquote>sotrovimab的可用临床数据有限。使用sotrovimab可能会发生以前未报告的严重和意外不良事件。</blockquote></p><p> <b>Hypersensitivity Including Anaphylaxis and Infusion-Related Reactions</b></p><p><blockquote><b>超敏反应，包括过敏反应和输液相关反应</b></blockquote></p><p> Serious hypersensitivity reactions, including anaphylaxis, have been observed with administration of sotrovimab. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive care.</p><p><blockquote>服用sotrovimab后观察到严重的超敏反应，包括过敏反应。如果出现临床上显著的超敏反应或过敏反应的体征和症状，立即停止给药并开始适当的药物和/或支持性护理。</blockquote></p><p> Infusion-related reactions, occurring during the infusion and up to 24 hours after the infusion, have been observed with administration of sotrovimab. These reactions may be severe or life threatening.</p><p><blockquote>服用sotrovimab时观察到输注期间和输注后24小时内发生的输注相关反应。这些反应可能很严重或危及生命。</blockquote></p><p> Signs and symptoms of infusion-related reactions may include: fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (eg, atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, vaso-vagal reactions (eg, pre-syncope, syncope), dizziness and diaphoresis.</p><p><blockquote>输注相关反应的体征和症状可能包括：发热、呼吸困难、氧饱和度降低、寒战、疲劳、心律失常（如房颤、窦性心动过速、心动过缓）、胸痛或不适、虚弱、精神状态改变、恶心、头痛、支气管痉挛、低血压、高血压、血管水肿、咽喉刺激、皮疹（包括荨麻疹）、瘙痒、肌痛、血管迷走神经反应（如晕厥前、晕厥）、头晕和出汗。</blockquote></p><p> Consider slowing or stopping the infusion and administer appropriate medications and/or supportive care if an infusion-related reaction occurs.</p><p><blockquote>如果发生输注相关反应，考虑减慢或停止输注，并给予适当的药物和/或支持性护理。</blockquote></p><p> Hypersensitivity reactions occurring more than 24 hours after the infusion have also been reported with the use of SARS-CoV-2 monoclonal antibodies under Emergency Use Authorization.</p><p><blockquote>在紧急使用授权下使用新型冠状病毒单克隆抗体时，也报告了输注后超过24小时发生的超敏反应。</blockquote></p><p> <b>Clinical Worsening After SARS-CoV-2 Monoclonal Antibody Administration</b></p><p><blockquote><b>新型冠状病毒单克隆抗体给药后临床恶化</b></blockquote></p><p> Clinical worsening of COVID‑19 after administration of SARS-CoV-2 monoclonal antibody treatment has been reported and may include signs or symptoms of fever, hypoxia or increased respiratory difficulty, arrhythmia (eg, atrial fibrillation, tachycardia, bradycardia), fatigue and altered mental status. Some of these events required hospitalization. It is not known if these events were related to SARS-CoV-2 monoclonal antibody use or were due to progression of COVID‑19.</p><p><blockquote>据报道，接受新型冠状病毒单克隆抗体治疗后，COVID-19的临床恶化可能包括发热、缺氧或呼吸困难增加、心律失常（如房颤、心动过速、心动过缓）、疲劳和精神状态改变的体征或症状。其中一些事件需要住院治疗。尚不清楚这些事件是与新型冠状病毒单克隆抗体的使用有关，还是由于COVID-19的进展。</blockquote></p><p> <b>Limitations of Benefit and Potential for Risk in Patients with Severe COVID‑19</b></p><p><blockquote><b>重症COVID-19患者的获益限制和潜在风险</b></blockquote></p><p> Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID‑19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID‑19 requiring high flow oxygen or mechanical ventilation. Therefore, sotrovimab is not authorized for use in patients: who are hospitalized due to COVID‑19, OR who require oxygen therapy due to COVID‑19 OR who require an increase in baseline oxygen flow rate due to COVID‑19 in those on chronic oxygen therapy due to underlying non‑COVID‑19 related comorbidity.</p><p><blockquote>在因COVID-19住院的患者中未观察到sotrovimab治疗的益处。当给予需要高流量氧气或机械通气的COVID-19住院患者时，新型冠状病毒单克隆抗体可能与更差的临床结局相关。因此，sotrovimab未被授权用于以下患者：因COVID-19住院的患者，或因COVID-19需要氧疗的患者，或因COVID-19需要增加基线氧流量的患者，以及因潜在的非COVID-19相关合并症而接受慢性氧疗的患者。</blockquote></p><p> <b>ADVERSE EVENTS</b></p><p><blockquote><b>不良事件</b></blockquote></p><p> Hypersensitivity adverse reactions have been observed in 2% of patients treated with sotrovimab and 1% with placebo in COMET-ICE.</p><p><blockquote>在COMET-ICE中，在2%接受sotrovimab治疗的患者和1%接受安慰剂治疗的患者中观察到超敏反应。</blockquote></p><p> The most common treatment-emergent adverse events observed in the sotrovimab treatment group in COMET-ICE were rash (1%) and diarrhea (2%), all of which were Grade 1 (mild) or Grade 2 (moderate). No other treatment-emergent adverse events were reported at a higher rate with sotrovimab compared to placebo.</p><p><blockquote>COMET-ICE中sotrovimab治疗组观察到的最常见的治疗后出现的不良事件为皮疹（1%）和腹泻（2%），均为1级（轻度）或2级（中度）。与安慰剂相比，sotrovimab组未报告其他治疗中出现的不良事件发生率更高。</blockquote></p><p> <b>USE IN SPECIFIC POPULATIONS</b></p><p><blockquote><b>用于特定人群</b></blockquote></p><p> <b>Pregnancy</b></p><p><blockquote><b>妊娠</b></blockquote></p><p></p><p> There are insufficient data to evaluate a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcome. Sotrovimab should be used during pregnancy only if the potential benefit justifies the potential risk for the mother and the fetus.</p><p><blockquote>没有足够的数据来评估药物相关的重大出生缺陷、流产或不良母体或胎儿结局的风险。只有当潜在益处证明对母亲和胎儿的潜在风险合理时，才应在妊娠期间使用Sotrovimab。</blockquote></p><p> <b>Lactation</b></p><p><blockquote><b>哺乳期</b></blockquote></p><p> There are no available data on the presence of sotrovimab in human milk, the effects on the breastfed infant or the effects on milk production. Individuals with COVID-19 who are breastfeeding should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.</p><p><blockquote>没有关于母乳中sotrovimab的存在、对母乳喂养婴儿的影响或对产奶量的影响的可用数据。正在母乳喂养的新冠肺炎患者应遵循临床指南的做法，以避免婴儿接触新冠肺炎。</blockquote></p><p> <b>About theVir andGSKCollaboration</b>In April 2020, Vir and GSK entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration uses Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventive options to help address the current COVID-19 pandemic and future outbreaks. The companies will leverage GSK’s expertise in functional genomics and combine their capabilities in CRISPR screening and artificial intelligence to identify anti-coronavirus compounds that target cellular host genes. They will also apply their combined expertise to research SARS-CoV-2 and other coronavirus vaccines.</p><p><blockquote><b>关于theVir和GSK合作</b>2020年4月，Vir和GSK达成合作，研究和开发冠状病毒的解决方案，包括导致COVID-19的新型冠状病毒病毒。此次合作使用Vir专有的单克隆抗体平台技术来加速现有的和识别新的抗病毒抗体，这些抗体可用作治疗或预防选择，以帮助应对当前的新冠肺炎疫情和未来的疫情。两家公司将利用GSK在功能基因组学方面的专业知识，并结合其在CRISPR筛选和人工智能方面的能力，以识别靶向细胞宿主基因的抗冠状病毒化合物。他们还将运用他们的综合专业知识来研究新型冠状病毒和其他冠状病毒疫苗。</blockquote></p><p> <b>GSKCommitment toTackling COVID-19</b></p><p><blockquote><b>GSK致力于应对COVID-19</b></blockquote></p><p> GSK’s response to COVID-19 has been one of the broadest in the industry, with potential treatments in addition to our vaccine candidates in development with partner organizations.</p><p><blockquote>葛兰素史克对COVID-19的反应是业内最广泛的反应之一，除了我们与合作伙伴组织正在开发的候选疫苗之外，还提供了潜在的治疗方法。</blockquote></p><p> GSK is collaborating with several organizations on COVID-19 vaccines by providing access to our adjuvant technology. We are working with Sanofi SA, Medicago Inc. and SK bioscience Co., Ltd. to&nbsp;develop&nbsp;adjuvanted, protein-based vaccine candidates, and&nbsp;all&nbsp;are&nbsp;now in Phase&nbsp;3&nbsp;clinical trials. The use of an adjuvant can be of particular importance in a pandemic since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and contributing to protecting more people in need.</p><p><blockquote>葛兰素史克正在与多个组织合作开发新冠肺炎疫苗，提供我们的佐剂技术。我们正在与Sanofi SA、Medicago Inc.和SK bioscience Co., Ltd.合作开发基于佐剂的蛋白质候选疫苗，目前均处于3期临床试验。佐剂的使用在大流行中可能特别重要，因为它可以减少每剂所需的疫苗蛋白的量，允许生产更多的疫苗剂量并有助于保护更多有需要的人。</blockquote></p><p> GSK is also working with mRNA specialist, CureVac NV, to jointly develop next-generation, optimized mRNA vaccines for COVID-19 with the potential to address multiple emerging variants in one vaccine.</p><p><blockquote>葛兰素史克还与mRNA专家CureVac NV合作，共同开发下一代优化的新冠肺炎mRNA疫苗，有可能在一种疫苗中解决多种新出现的变异。</blockquote></p><p> GSK is also exploring treatments for COVID-19 patients, collaborating with Vir Biotechnology to investigate monoclonal antibodies that could be used as therapeutic or preventive options for COVID-19.</p><p><blockquote>葛兰素史克还在探索新冠肺炎患者的治疗方法，与Vir Biotechnology合作研究可用作新冠肺炎治疗或预防选择的单克隆抗体。</blockquote></p><p> <b>Vir’sCommitment to COVID-19</b>Vir was founded with the mission of addressing the world’s most serious infectious diseases. In 2020, Vir responded rapidly to the COVID-19 pandemic by leveraging our unique scientific insights and industry-leading antibody platform to explore multiple monoclonal antibodies as potential therapeutic or preventive options for COVID-19. Sotrovimab is the first SARS-CoV-2-targeting antibody Vir advanced into the clinic. It was carefully selected for its demonstrated promise in preclinical research, including an anticipated high barrier to resistance and potential ability to both block the virus from entering healthy cells and clear infected cells. Vir is continuing to pursue novel therapeutic and prophylactic solutions to combat SARS-CoV-2 and future coronavirus pandemics, both independently and in collaboration with its partners.</p><p><blockquote><b>Vir对COVID-19的承诺</b>Vir成立的使命是解决世界上最严重的传染病。2020年，Vir利用我们独特的科学见解和行业领先的抗体平台，探索多种单克隆抗体作为COVID-19的潜在治疗或预防选择，迅速应对COVID-19大流行。Sotrovimab是第一个挺进临床的新型冠状病毒靶向抗体Vir。它被精心选择是因为它在临床前研究中表现出的前景，包括预期的高耐药性屏障和阻止病毒进入健康细胞和清除受感染细胞的潜在能力。Vir正在继续寻求新的治疗和预防解决方案，以应对新型冠状病毒和未来的冠状病毒大流行，无论是独立还是与其合作伙伴合作。</blockquote></p><p> <b>About GSK</b></p><p><blockquote><b>关于GSK</b></blockquote></p><p> GSK is a science-led global healthcare company. For further information please visitwww.gsk.com/aboutus.</p><p><blockquote>葛兰素史克是一家以科学为主导的全球医疗保健公司。欲了解更多信息，请访问www.gsk.com/aboutus。</blockquote></p><p> <b>About Vir Biotechnology</b></p><p><blockquote><b>关于维尔生物技术</b></blockquote></p><p> Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus. For more information, please visitwww.vir.bio.</p><p><blockquote>Vir Biotechnology是一家商业阶段的免疫学公司，专注于将免疫学见解与尖端技术相结合，以治疗和预防严重的传染病。Vir组装了四个技术平台，旨在通过利用对天然免疫过程的关键观察来刺激和增强免疫系统。其目前的开发管线包括针对COVID-19、乙型肝炎病毒、甲型流感和人类免疫缺陷病毒的候选产品。欲了解更多信息，请访问www.vir.bio。</blockquote></p><p> <b>GSK Cautionary Statement Regarding Forward-Looking Statements</b></p><p><blockquote><b>葛兰素史克关于前瞻性陈述的警告声明</b></blockquote></p><p> GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2020, GSK’s Q3 Results and any impacts of the COVID-19 pandemic.</p><p><blockquote>葛兰素史克提醒投资者，葛兰素史克做出的任何前瞻性陈述或预测，包括本公告中做出的陈述或预测，都受到风险和不确定性的影响，可能导致实际结果与预测结果存在重大差异。这些因素包括但不限于公司2020年20-F表格年度报告中描述的因素、葛兰素史克第三季度业绩以及COVID-19大流行的任何影响。</blockquote></p><p></p><p> <b>Vir Forward-Looking Statements</b>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “plan,” “potential,” “aim,” “promising” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Vir’s expectations and assumptions as of the date of this press release. Forward-looking statements contained in this press release include, but are not limited to, statements regarding the ability of sotrovimab to treat and/or prevent COVID-19 either through IV or IM administration, Vir’s collaboration with GSK, plans to progress regulatory submissions globally, including with the FDA regarding the existing EUA for sotrovimab, planned discussions with other global regulatory agencies, the timing of availability of clinical data, program updates and data disclosures, the clinical development program for sotrovimab, and the ability of sotrovimab to maintain activity against circulating variants of concern and interest, including key mutations of Omicron. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, challenges in the treatment of hospitalized patients, difficulties in collaborating with other companies or government agencies, challenges in accessing manufacturing capacity, successful development and/or commercialization of alternative product candidates by Vir’s competitors, changes in expected or existing competition, delays in or disruptions to Vir’s business or clinical trials due to the COVID-19 pandemic, geopolitical changes or other external factors, and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Vir’s filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as required by law, Vir assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.</p><p><blockquote><b>Vir前瞻性陈述</b>本新闻稿包含1995年《私人证券诉讼改革法案》含义内的前瞻性陈述。诸如“可能”、“将”、“计划”、“潜力”、“目标”、“承诺”和类似表达（以及提及未来事件、条件或情况的其他词语或表达）旨在识别前瞻性陈述。这些前瞻性陈述基于Vir截至本新闻稿发布之日的预期和假设。本新闻稿中包含的前瞻性声明包括但不限于有关sotrovimab通过静脉注射或肌肉注射治疗和/或预防COVID-19的能力、Vir与GSK的合作、在全球范围内推进监管提交的计划，包括与FDA就sotrovimab现有EUA进行的计划讨论、临床数据可用性、计划更新和数据披露的时间、sotrovimab的临床开发计划以及sotrovimab维持针对令人担忧和感兴趣的循环变异体（包括奥密克戎病的关键突变）的活性的能力。许多因素可能导致当前预期和实际结果之间的差异，包括在临床前或临床研究期间观察到的意外安全性或疗效数据、住院患者治疗中的挑战、与其他公司或政府机构合作的困难、获得制造能力的挑战、Vir的竞争对手成功开发和/或商业化替代候选产品、预期或现有竞争的变化、由于COVID-19大流行、地缘政治变化或其他外部因素导致Vir的业务或临床试验延迟或中断，以及意外的诉讼或其他纠纷。Vir向美国证券交易委员会提交的文件中讨论了可能导致实际结果与本新闻稿中前瞻性陈述中明示或暗示的结果不同的其他因素，包括其中包含的标题为“风险因素”的部分。除非法律要求，Vir不承担更新此处包含的任何前瞻性陈述以反映预期的任何变化的义务，即使有新信息可用。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.globenewswire.com/news-release/2021/12/02/2344688/0/en/Preclinical-Data-Demonstrate-Sotrovimab-Retains-Activity-Against-Key-Omicron-Mutations-New-SARS-CoV-2-Variant.html\">GlobeNewswire</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GSK":"葛兰素史克"},"source_url":"https://www.globenewswire.com/news-release/2021/12/02/2344688/0/en/Preclinical-Data-Demonstrate-Sotrovimab-Retains-Activity-Against-Key-Omicron-Mutations-New-SARS-CoV-2-Variant.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1195275859","content_text":"LONDON and SAN FRANCISCO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced an update tobioRxiv, a preprint server, with preclinical data demonstrating that sotrovimab, an investigational monoclonal antibody, retains activity against key mutations1of the new Omicron SARS-CoV-2 variant (B.1.1.529), including those found in the binding site of sotrovimab. These data were generated through pseudo-virus testing of specific individual mutations found in Omicron. To date, sotrovimab has demonstrated ongoing activity against all tested variants of concern and interest defined by the World Health Organization (WHO). The companies are now completing in vitro pseudo-virus testing to confirm the neutralizing activity of sotrovimab against the combination of all the Omicron mutations with the intent to provide an update by the end of 2021.\nGeorge Scangos, Ph.D., Chief Executive Officer of Vir, said:“Sotrovimab was deliberately designed with a mutating virus in mind. By targeting a highly conserved region of the spike protein that is less likely to mutate, we hoped to address both the current SARS-CoV-2 virus and future variants that we expected would be inevitable. This hypothesis has borne out again and again – with its ongoing ability to maintain activity against all tested variants of concern and interest to date, including key mutations found in Omicron, as demonstrated by pre-clinical data. We have every expectation that this positive trend will continue and are working rapidly to confirm its activity against the full combination sequence of Omicron.”\nDr.Hal Barron, Chief Scientific Officer and President R&D, GSK, said:“Since the beginning of the pandemic, we have been working with Vir to combine our scientific expertise and technologies to deliver an enduring treatment option for patients with COVID-19. Though early, these pre-clinical data support our long-held view on the potential for sotrovimab to maintain its activity as the virus continues to mutate. We are pleased that this treatment option is available to patients in the US and many other countries, and are working to expand access worldwide.”\nAbout SotrovimabSotrovimab is an investigational SARS-CoV-2 neutralizing monoclonal antibody. The antibody binds to an epitope on SARS-CoV-2 shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop. Sotrovimab, which incorporates Xencor’s Xtend™ technology, has also been designed to achieve high concentration in the lungs to ensure optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life.\nUpdated in vitro data, published in bioRxiv, demonstrate that sotrovimab retains activity against all current tested variants of concern and interest of the SARS-CoV-2 virus as defined by WHO, plus others, including but not limited to Delta (B.1.617.2), Delta Plus (AY.1 or AY.2), Mu (B.1.621) and key mutations of Omicron (B.1.1.529).\nAbout the sotrovimab clinical development program\n\nCOMET-ICE: a Phase 3, multi-center, double-blind, placebo-controlled trial investigated an intravenous (IV) infusion of sotrovimab in adults with mild-to-moderate COVID-19 at high risk of progression to severe disease, who are not hospitalized and not requiring oxygen. The final COMET-ICE trial results in the full trial population of 1,057 participants demonstrated a 79% reduction (adjusted relative risk reduction) (p<0.001) in hospitalization for more than 24 hours or death due to any cause by Day 29 compared to placebo, meeting the primary endpoint of the trial. Interim data were published inThe New England Journal of Medicineon October 27, 2021 and final data were pre-published on November 8, 2021 onmedRxiv.\nCOMET-TAIL: a Phase 3, randomized, multi-center, open-label, non-inferiority trial of intramuscular (IM) versus IV administration of sotrovimab for the early treatment of mild-to-moderate COVID-19 in high-risk non-hospitalized adult and pediatric patients (12 years of age and older). The trial’s primary endpoint was met, and headline data demonstrated that intramuscularly administered sotrovimab was non-inferior and offered similar efficacy to intravenous administration for high-risk populations. The companies plan to submit the complete COMET-TAIL data set to a peer-reviewed journal for publication in the first quarter of 2022.\nCOMET-PEAK: a Phase 2, randomized, multi-center, parallel-group trial evaluating IV and IM administration of sotrovimab in outpatients with mild-to-moderate COVID-19. Data available to date from open-label Part B of the trial (500mg IV vs. 500mg IM) demonstrated equivalence on the virological response between the IM and IV arms. The companies plan to submit the complete COMET-PEAK data set to a peer-reviewed journal for publication in due course.\nGSK and Vir are also partnering to investigate the use of sotrovimab in uninfected immunocompromised adults to determine whether sotrovimab can prevent symptomatic COVID-19 infection. GSK and Vir are supporting investigator-sponsored studies and fostering scientific collaborations with experienced investigators and networks involved in the continuum of care of immunocompromised patients, to understand the role sotrovimab for prophylaxis could play in this population. Discussions with regulatory authorities regarding the prophylaxis program will take place in due course.\n\nAbout global access to sotrovimab\n\nSotrovimab is authorized for emergency use in the United States. Xevudy (sotrovimab) received apositive scientific opinionunder Article 5(3) of Regulation 726/2004 from the Committee for Human Medicinal Products (CHMP) in the EU, has been granted a provisional marketing authorization in Australia, and conditional marketing authorization in Saudi Arabia. In Japan, it has been approved via the Special Approval for Emergency Pathway. Temporary authorizations for sotrovimab have been granted in a dozen countries.\nGSK and Vir also recently submitted the Marketing Authorization Application (MAA) to the European Medicines Agency for Xevudy (sotrovimab) for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (COVID-19) who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19.\nSotrovimab is supplied in several countries worldwide, including through national agreements in the United States, United Kingdom, Japan, Australia, Canada, Singapore, Switzerland and United Arab Emirates. We have also signed a Joint Procurement Agreement with the European Commission to supply doses of sotrovimab. Additional agreements are yet to be announced due to confidentiality or regulatory requirements.\n\nSotrovimab in the United StatesThe following is a summary of information for sotrovimab. Healthcare providers in the U.S. should review the Fact Sheets for information about the authorized use of sotrovimab and mandatory requirements of the EUA. Please see theFood and Drug Administration (FDA) Letter of Authorization, fullFact Sheet for Healthcare Providersand fullFact Sheet for Patients, Parents, and Caregivers.\nSotrovimab has been authorized by the US FDA for the emergency use described below. Sotrovimab is not FDA-approved for this use.\nSotrovimab is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of sotrovimab under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.\nAuthorized UseThe U.S. FDA has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product sotrovimab for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.\nLimitations of Authorized UseSotrovimab is not authorized for use in patients:\n\nwho are hospitalized due to COVID-19, OR\nwho require oxygen therapy due to COVID-19, OR\nwho require an increase in baseline oxygen flow rate due to COVID-19 (in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity)\n\nBenefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID‑19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID‑19 requiring high flow oxygen or mechanical ventilation.\nImportant Safety Information\nCONTRAINDICATIONS\nSotrovimab is contraindicated in patients who have a history of anaphylaxis to sotrovimab or to any of the excipients in the formulation.\nWARNINGS AND PRECAUTIONS\nThere are limited clinical data available for sotrovimab. Serious and unexpected adverse events may occur that have not been previously reported with sotrovimab use.\nHypersensitivity Including Anaphylaxis and Infusion-Related Reactions\nSerious hypersensitivity reactions, including anaphylaxis, have been observed with administration of sotrovimab. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive care.\nInfusion-related reactions, occurring during the infusion and up to 24 hours after the infusion, have been observed with administration of sotrovimab. These reactions may be severe or life threatening.\nSigns and symptoms of infusion-related reactions may include: fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (eg, atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, vaso-vagal reactions (eg, pre-syncope, syncope), dizziness and diaphoresis.\nConsider slowing or stopping the infusion and administer appropriate medications and/or supportive care if an infusion-related reaction occurs.\nHypersensitivity reactions occurring more than 24 hours after the infusion have also been reported with the use of SARS-CoV-2 monoclonal antibodies under Emergency Use Authorization.\nClinical Worsening After SARS-CoV-2 Monoclonal Antibody Administration\nClinical worsening of COVID‑19 after administration of SARS-CoV-2 monoclonal antibody treatment has been reported and may include signs or symptoms of fever, hypoxia or increased respiratory difficulty, arrhythmia (eg, atrial fibrillation, tachycardia, bradycardia), fatigue and altered mental status. Some of these events required hospitalization. It is not known if these events were related to SARS-CoV-2 monoclonal antibody use or were due to progression of COVID‑19.\nLimitations of Benefit and Potential for Risk in Patients with Severe COVID‑19\nBenefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID‑19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID‑19 requiring high flow oxygen or mechanical ventilation. Therefore, sotrovimab is not authorized for use in patients: who are hospitalized due to COVID‑19, OR who require oxygen therapy due to COVID‑19 OR who require an increase in baseline oxygen flow rate due to COVID‑19 in those on chronic oxygen therapy due to underlying non‑COVID‑19 related comorbidity.\nADVERSE EVENTS\nHypersensitivity adverse reactions have been observed in 2% of patients treated with sotrovimab and 1% with placebo in COMET-ICE.\nThe most common treatment-emergent adverse events observed in the sotrovimab treatment group in COMET-ICE were rash (1%) and diarrhea (2%), all of which were Grade 1 (mild) or Grade 2 (moderate). No other treatment-emergent adverse events were reported at a higher rate with sotrovimab compared to placebo.\nUSE IN SPECIFIC POPULATIONS\nPregnancy\nThere are insufficient data to evaluate a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcome. Sotrovimab should be used during pregnancy only if the potential benefit justifies the potential risk for the mother and the fetus.\nLactation\nThere are no available data on the presence of sotrovimab in human milk, the effects on the breastfed infant or the effects on milk production. Individuals with COVID-19 who are breastfeeding should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.\nAbout theVir andGSKCollaborationIn April 2020, Vir and GSK entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration uses Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventive options to help address the current COVID-19 pandemic and future outbreaks. The companies will leverage GSK’s expertise in functional genomics and combine their capabilities in CRISPR screening and artificial intelligence to identify anti-coronavirus compounds that target cellular host genes. They will also apply their combined expertise to research SARS-CoV-2 and other coronavirus vaccines.\nGSKCommitment toTackling COVID-19\nGSK’s response to COVID-19 has been one of the broadest in the industry, with potential treatments in addition to our vaccine candidates in development with partner organizations.\nGSK is collaborating with several organizations on COVID-19 vaccines by providing access to our adjuvant technology. We are working with Sanofi SA, Medicago Inc. and SK bioscience Co., Ltd. to develop adjuvanted, protein-based vaccine candidates, and all are now in Phase 3 clinical trials. The use of an adjuvant can be of particular importance in a pandemic since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and contributing to protecting more people in need.\nGSK is also working with mRNA specialist, CureVac NV, to jointly develop next-generation, optimized mRNA vaccines for COVID-19 with the potential to address multiple emerging variants in one vaccine.\nGSK is also exploring treatments for COVID-19 patients, collaborating with Vir Biotechnology to investigate monoclonal antibodies that could be used as therapeutic or preventive options for COVID-19.\nVir’sCommitment to COVID-19Vir was founded with the mission of addressing the world’s most serious infectious diseases. In 2020, Vir responded rapidly to the COVID-19 pandemic by leveraging our unique scientific insights and industry-leading antibody platform to explore multiple monoclonal antibodies as potential therapeutic or preventive options for COVID-19. Sotrovimab is the first SARS-CoV-2-targeting antibody Vir advanced into the clinic. It was carefully selected for its demonstrated promise in preclinical research, including an anticipated high barrier to resistance and potential ability to both block the virus from entering healthy cells and clear infected cells. Vir is continuing to pursue novel therapeutic and prophylactic solutions to combat SARS-CoV-2 and future coronavirus pandemics, both independently and in collaboration with its partners.\nAbout GSK\nGSK is a science-led global healthcare company. For further information please visitwww.gsk.com/aboutus.\nAbout Vir Biotechnology\nVir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus. For more information, please visitwww.vir.bio.\nGSK Cautionary Statement Regarding Forward-Looking Statements\nGSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2020, GSK’s Q3 Results and any impacts of the COVID-19 pandemic.\nVir Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “plan,” “potential,” “aim,” “promising” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Vir’s expectations and assumptions as of the date of this press release. Forward-looking statements contained in this press release include, but are not limited to, statements regarding the ability of sotrovimab to treat and/or prevent COVID-19 either through IV or IM administration, Vir’s collaboration with GSK, plans to progress regulatory submissions globally, including with the FDA regarding the existing EUA for sotrovimab, planned discussions with other global regulatory agencies, the timing of availability of clinical data, program updates and data disclosures, the clinical development program for sotrovimab, and the ability of sotrovimab to maintain activity against circulating variants of concern and interest, including key mutations of Omicron. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, challenges in the treatment of hospitalized patients, difficulties in collaborating with other companies or government agencies, challenges in accessing manufacturing capacity, successful development and/or commercialization of alternative product candidates by Vir’s competitors, changes in expected or existing competition, delays in or disruptions to Vir’s business or clinical trials due to the COVID-19 pandemic, geopolitical changes or other external factors, and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Vir’s filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as required by law, Vir assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.","news_type":1,"symbols_score_info":{"GSK":0.9}},"isVote":1,"tweetType":1,"viewCount":1729,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603566092,"gmtCreate":1638429065241,"gmtModify":1638429065315,"author":{"id":"4099680250879430","authorId":"4099680250879430","name":"lomenet65","avatar":"https://static.tigerbbs.com/a92a300242412a0d7cd11dbac51daaab","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099680250879430","idStr":"4099680250879430"},"themes":[],"title":"","htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603566092","repostId":"1101300146","repostType":2,"repost":{"id":"1101300146","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638428501,"share":"https://www.laohu8.com/m/news/1101300146?lang=zh_CN&edition=full","pubTime":"2021-12-02 15:01","market":"us","language":"en","title":"Dow Jones futures rose nearly 1%, S&P 500 futures rose 0.85%, Nasdaq 100 futures rose 0.64%.<blockquote>道琼斯期货涨近1%，标普500期货涨0.85%，纳斯达克100期货涨0.64%。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1101300146","media":"Tiger Newspress","summary":"Dow Jones futures rose nearly 1%, S&P 500 futures rose 0.85%, Nasdaq 100 futures rose 0.64%.","content":"<p>Dow Jones futures rose&nbsp;nearly 1%, S&amp;P 500 futures rose 0.85%, Nasdaq 100 futures rose 0.64%.<img src=\"https://static.tigerbbs.com/7cc5fbc2c078d2e811d0be03d2c4950f\" tg-width=\"542\" tg-height=\"184\" width=\"100%\" height=\"auto\"></p><p><blockquote>道琼斯期货涨近1%，标普500期货涨0.85%，纳斯达克100期货涨0.64%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dow Jones futures rose nearly 1%, S&P 500 futures rose 0.85%, Nasdaq 100 futures rose 0.64%.<blockquote>道琼斯期货涨近1%，标普500期货涨0.85%，纳斯达克100期货涨0.64%。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDow Jones futures rose nearly 1%, S&P 500 futures rose 0.85%, Nasdaq 100 futures rose 0.64%.<blockquote>道琼斯期货涨近1%，标普500期货涨0.85%，纳斯达克100期货涨0.64%。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-02 15:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Dow Jones futures rose&nbsp;nearly 1%, S&amp;P 500 futures rose 0.85%, Nasdaq 100 futures rose 0.64%.<img src=\"https://static.tigerbbs.com/7cc5fbc2c078d2e811d0be03d2c4950f\" tg-width=\"542\" tg-height=\"184\" width=\"100%\" height=\"auto\"></p><p><blockquote>道琼斯期货涨近1%，标普500期货涨0.85%，纳斯达克100期货涨0.64%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101300146","content_text":"Dow Jones futures rose nearly 1%, S&P 500 futures rose 0.85%, Nasdaq 100 futures rose 0.64%.","news_type":1,"symbols_score_info":{"ESmain":0.9,"YMmain":0.9,"NQmain":0.9}},"isVote":1,"tweetType":1,"viewCount":1672,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600508839,"gmtCreate":1638166675841,"gmtModify":1638166675841,"author":{"id":"4099680250879430","authorId":"4099680250879430","name":"lomenet65","avatar":"https://static.tigerbbs.com/a92a300242412a0d7cd11dbac51daaab","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099680250879430","idStr":"4099680250879430"},"themes":[],"title":"","htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600508839","repostId":"600292002","repostType":1,"repost":{"id":600292002,"gmtCreate":1638154130902,"gmtModify":1706055645791,"author":{"id":"3527667596890271","authorId":"3527667596890271","name":"Buy_Sell","avatar":"https://static.tigerbbs.com/a5f0ed79a338c758a22e0b4ea13bf9d2","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3527667596890271","idStr":"3527667596890271"},"themes":[],"title":"🔥【11月29日】看本周关键事件，聊今日交易计划","htmlText":"聊聊今日份的交易想法，包括对于大盘走势后续的看法？看涨/看跌哪只股票、晒晒单等等。 港股市场 11月29日讯，新毒株来袭，港股三大指数集体低开，恒指跌0.71%报23910点，国指跌0.2%报8558点，恒生科技指数跌0.87%报6098点。 盘面上，受疫情影响的濠赌股、航空股、石油股、餐饮股集体下挫，<a target=\"_blank\" href=\"https://laohu8.com/S/01128\">$永利澳门(01128)$</a> 大跌超10%，<a target=\"_blank\" href=\"https://laohu8.com/S/01876\">$百威亚太(01876)$</a> 、<a target=\"_blank\" href=\"https://laohu8.com/S/00753\">$中国国航(00753)$</a> 等均有跌幅；手机概念股、光伏股、保险股、汽车股、电力股、煤炭股齐跌；大型科技股涨跌各异，<a target=\"_blank\" href=\"https://laohu8.com/S/03690\">$美团-W(03690)$</a> 大跌近9%，<a target=\"_blank\" href=\"https://laohu8.com/S/00700\">$腾讯控股(00700)$</a> 跌0.3%，<a target=\"_blank\" href=\"https://laohu8.com/S/09988\">$阿里巴巴-SW(09988)$</a> 涨3%。另一方面，抗疫概念股逆势高开，康希诺生物涨超9%，开拓药业、复星医药皆上涨，烟草概念股、海运股走强。 多重利空叠加，永利澳门跌超10%。美团低开近9%。此前财报显示，季度亏损创2018年以来最大。新毒株出现以及周焯华被批捕等多重利空叠加，港股濠赌股开盘集体重挫。永利澳门跌超10%，银河娱乐、金沙中国和","listText":"聊聊今日份的交易想法，包括对于大盘走势后续的看法？看涨/看跌哪只股票、晒晒单等等。 港股市场 11月29日讯，新毒株来袭，港股三大指数集体低开，恒指跌0.71%报23910点，国指跌0.2%报8558点，恒生科技指数跌0.87%报6098点。 盘面上，受疫情影响的濠赌股、航空股、石油股、餐饮股集体下挫，<a target=\"_blank\" href=\"https://laohu8.com/S/01128\">$永利澳门(01128)$</a> 大跌超10%，<a target=\"_blank\" href=\"https://laohu8.com/S/01876\">$百威亚太(01876)$</a> 、<a target=\"_blank\" href=\"https://laohu8.com/S/00753\">$中国国航(00753)$</a> 等均有跌幅；手机概念股、光伏股、保险股、汽车股、电力股、煤炭股齐跌；大型科技股涨跌各异，<a target=\"_blank\" href=\"https://laohu8.com/S/03690\">$美团-W(03690)$</a> 大跌近9%，<a target=\"_blank\" href=\"https://laohu8.com/S/00700\">$腾讯控股(00700)$</a> 跌0.3%，<a target=\"_blank\" href=\"https://laohu8.com/S/09988\">$阿里巴巴-SW(09988)$</a> 涨3%。另一方面，抗疫概念股逆势高开，康希诺生物涨超9%，开拓药业、复星医药皆上涨，烟草概念股、海运股走强。 多重利空叠加，永利澳门跌超10%。美团低开近9%。此前财报显示，季度亏损创2018年以来最大。新毒株出现以及周焯华被批捕等多重利空叠加，港股濠赌股开盘集体重挫。永利澳门跌超10%，银河娱乐、金沙中国和","text":"聊聊今日份的交易想法，包括对于大盘走势后续的看法？看涨/看跌哪只股票、晒晒单等等。 港股市场 11月29日讯，新毒株来袭，港股三大指数集体低开，恒指跌0.71%报23910点，国指跌0.2%报8558点，恒生科技指数跌0.87%报6098点。 盘面上，受疫情影响的濠赌股、航空股、石油股、餐饮股集体下挫，$永利澳门(01128)$ 大跌超10%，$百威亚太(01876)$ 、$中国国航(00753)$ 等均有跌幅；手机概念股、光伏股、保险股、汽车股、电力股、煤炭股齐跌；大型科技股涨跌各异，$美团-W(03690)$ 大跌近9%，$腾讯控股(00700)$ 跌0.3%，$阿里巴巴-SW(09988)$ 涨3%。另一方面，抗疫概念股逆势高开，康希诺生物涨超9%，开拓药业、复星医药皆上涨，烟草概念股、海运股走强。 多重利空叠加，永利澳门跌超10%。美团低开近9%。此前财报显示，季度亏损创2018年以来最大。新毒株出现以及周焯华被批捕等多重利空叠加，港股濠赌股开盘集体重挫。永利澳门跌超10%，银河娱乐、金沙中国和","images":[{"img":"https://static.tigerbbs.com/f61370234bdf1731769f703d6598becd","width":"300","height":"300"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600292002","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"subType":2,"comments":[],"imageCount":2,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2023,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600503138,"gmtCreate":1638166496234,"gmtModify":1638166548278,"author":{"id":"4099680250879430","authorId":"4099680250879430","name":"lomenet65","avatar":"https://static.tigerbbs.com/a92a300242412a0d7cd11dbac51daaab","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099680250879430","idStr":"4099680250879430"},"themes":[],"title":"","htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600503138","repostId":"1123251711","repostType":4,"isVote":1,"tweetType":1,"viewCount":1925,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600503942,"gmtCreate":1638166482809,"gmtModify":1638166548240,"author":{"id":"4099680250879430","authorId":"4099680250879430","name":"lomenet65","avatar":"https://static.tigerbbs.com/a92a300242412a0d7cd11dbac51daaab","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099680250879430","idStr":"4099680250879430"},"themes":[],"title":"","htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600503942","repostId":"1124072014","repostType":4,"repost":{"id":"1124072014","kind":"news","pubTimestamp":1638140765,"share":"https://www.laohu8.com/m/news/1124072014?lang=zh_CN&edition=full","pubTime":"2021-11-29 07:06","market":"us","language":"en","title":"November jobs report: What to know this week<blockquote>11月就业报告：本周需要了解什么</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1124072014","media":"yahoo","summary":"As investors return from the Thanksgiving-shortened trading week, focus will shift to the U.S. labor","content":"<p>As investors return from the Thanksgiving-shortened trading week, focus will shift to the U.S. labor market.</p><p><blockquote>随着投资者从感恩节缩短的交易周回归，焦点将转向美国劳动力市场。</blockquote></p><p> The Labor Department's monthly jobs report due for release on Friday is set to provide an updated snapshot of the strength in hiring and labor force participation in the U.S. economy. Consensus economists are looking for a half-million jobs to have returned in November, with the pace of hiring slowing only slightly from October's 531,000 gain. The unemployment rate is also expected to improve further to 4.5% from October's 4.6%, reaching the lowest level since March 2020.</p><p><blockquote>美国劳工部将于周五发布的月度就业报告将提供美国经济中招聘和劳动力参与实力的最新快照。经济学家一致认为，11月份将有50万个工作岗位回归，招聘速度仅较10月份的531,000个略有放缓。失业率也有望从10月的4.6%进一步改善至4.5%，达到2020年3月以来的最低水平。</blockquote></p><p> \"We expect non-farm payrolls to have risen by 500,000 in November, but the growing risk of a winter COVID wave and a dwindling supply of available workers will weigh on jobs growth soon,\" wrote Paul Ashworth, chief North America economist for Capital Economics, in a note last week.</p><p><blockquote>凯投宏观(Capital Economics)首席北美经济学家保罗·阿什沃斯(Paul Ashworth)写道：“我们预计11月份非农就业人数将增加50万人，但冬季新冠疫情风险不断增加以及可用工人供应减少将很快拖累就业增长。”在上周的一份报告中。</blockquote></p><p> \"Employment growth can’t continue at this pace for much longer unless the labor force stages a more notable recovery. If anything, labor supply could<i>worsen</i>over the coming months as the federal vaccine mandate covering 100 [million] workers begins on January 4,\" Ashworth added. \"That suggests wage growth will remain strong, and we expect a 0.4% [month-over-month] rise in average hourly earnings in October.\"</p><p><blockquote>“除非劳动力出现更显著的复苏，否则就业增长不可能以这种速度持续太久。如果说有什么不同的话，那就是劳动力供应可以<i>恶化</i>随着覆盖1亿工人的联邦疫苗授权于1月4日开始，未来几个月，”阿什沃斯补充道。“这表明工资增长将保持强劲，我们预计10月份平均时薪将[环比]增长0.4%。”</blockquote></p><p> On a year-over-year basis, average hourly earnings are expected to rise by 5.0%, accelerating even further after October's already marked 4.9% rise and representing the fastest wage growth rate since February.</p><p><blockquote>与去年同期相比，平均时薪预计将增长5.0%，继10月份已经显着增长4.9%之后进一步加速，这是自2月份以来最快的工资增长率。</blockquote></p><p> Growing average wages and a tight labor market — while a positive for consumers and their ability to spend — has also stoked concerns over persistent inflation. Last week's Personal Consumption Expenditures (PCE) deflator from the Bureau of Economic Analysis for October showed an annual jump of 5.0% in the index, or the biggest rise since 1990. And the core PCE, or the Fed's preferred inflation gauge stripping out volatile food and energy prices, rose by 4.1% year-over-year — the most in three decades.</p><p><blockquote>平均工资增长和劳动力市场紧张虽然对消费者及其消费能力有利，但也引发了人们对持续通胀的担忧。上周经济分析局公布的10月份个人消费支出(PCE)平减指数显示，该指数年率上涨5.0%，创1990年以来最大涨幅。核心PCE（即美联储首选的剔除波动较大的食品和能源价格的通胀指标）同比上涨4.1%，为三十年来的最高水平。</blockquote></p><p> Other recent data have homed in on the tight labor market and presaged a potentially strong November jobs report. Last week'sinitial jobless claims fell to a 52-year low of 199,000, taking out both the prior pandemic-era low and pre-pandemic average for new first-time filings. This served as yet another point underscoring the steep competition for labor among U.S. employers, with companies attempting to hire and retain their existing workforces amid widespread labor shortages.</p><p><blockquote>最近的其他数据集中在紧张的劳动力市场上，并预示着11月份就业报告可能强劲。上周首次申请失业救济人数降至19.9万人的52年低点，打破了之前大流行时期的低点和大流行前新首次申请失业救济人数的平均值。这再次凸显了美国雇主之间对劳动力的激烈竞争，在劳动力普遍短缺的情况下，公司试图雇用和留住现有劳动力。</blockquote></p><p> Even given these lingering scarcities, the labor force participation rate has yet to return to pre-pandemic levels. The civilian labor force was still down by nearly 3 million participants compared to February 2020, with lingering concerns over the virus and adesire by many working-age individuals to seek out new roles with better flexibility and benefitsstill keeping many individuals on the sidelines of the workforce. Consensus economists expect the labor force participation rate to tick up only slightly in November to reach 61.7%, growing from October's 61.6% but coming in well below the 63.3% rate from February 2020.</p><p><blockquote>即使考虑到这些挥之不去的短缺，劳动力参与率仍未恢复到大流行前的水平。与2020年2月相比，平民劳动力仍减少了近300万参与者，对病毒的担忧挥之不去，许多工作年龄的人渴望寻找具有更好灵活性和福利的新角色，这仍然使许多人处于劳动力的边缘。经济学家普遍预计，11月份劳动力参与率仅略有上升，达到61.7%，高于10月份的61.6%，但远低于2020年2月的63.3%。</blockquote></p><p> Returning the economy back to pre-pandemic labor force participation levels and ensuring job gains are seen equitably across different groups has become a key focus for the Federal Reserve. And the distance still left to make up on these fronts has also been the biggest factor keeping the Fed ultra-accommodative with its monetary policy support, even after a parade of hotter-than-expected inflation reports that would appear to warrant a more hawkish policy tilt and a quicker-than-expected hike to interest rates.Fed Chair Jerome Powell's renomination to remain as head of the central bankfurther suggests the Fed's focus on the labor market as a critical informing factor for monetary policy will remain.</p><p><blockquote>将经济恢复到大流行前的劳动力参与水平，并确保不同群体公平地看到就业增长，已成为美联储的一个重点关注点。在这些方面仍有待弥补的距离也是美联储货币政策支持保持超宽松的最大因素，即使在一系列高于预期的通胀报告似乎需要采取更强硬的政策倾斜美联储主席杰罗姆·鲍威尔再次被提名继续担任央行行长进一步表明，美联储将继续关注劳动力市场，将其作为货币政策的关键信息因素。</blockquote></p><p> \"Market views for future Fed rate increases have been pulled forward aggressively in response to evidence that elevated inflation pressures are likely to persist for longer,\" wrote Deutsche Bank economist Justin Weidner in a note last week. \"However, as Chair Powell's November press conference made evident, prospects for the labor market to return to maximum employment remain a critical consideration for when the Fed will eventually begin to actively tighten monetary policy.\"</p><p><blockquote>德意志银行经济学家贾斯汀·魏德纳(Justin Weidner)上周在一份报告中写道：“由于有证据表明通胀压力上升可能会持续更长时间，市场对美联储未来加息的看法已大幅提前。”“然而，正如鲍威尔主席11月新闻发布会所表明的那样，劳动力市场恢复最大就业的前景仍然是美联储最终何时开始积极收紧货币政策的关键考虑因素。”</blockquote></p><p> Economic calendar</p><p><blockquote>经济日历</blockquote></p><p> <ul>  <li><b>Monday:</b>Pending home sales, month-over-month, October (0.7% expected, -2.3% in September); Dallas Federal Reserve Manufacturing Activity Index, November (17.0 expected, 14.6 in October)</p><p><blockquote><ul><li><b>星期一：</b>10月份待售房屋环比（预期0.7%，9月份-2.3%）；11月达拉斯联储制造业活动指数（预期17.0，10月14.6）</li></ul></blockquote></p><p></p><p></li>  <li><b>Tuesday:</b>FHFA House Price Index, month-over-month, September (1.2% expected, 1.0% in August); S&amp;P CoreLogic Case-Shiller 20-City Composite Index, month-over-month, September (1.30% expected, 1.17% in August); S&amp;P CoreLogic Case-Shiller 20-City Composite Index, September (19.66% during prior month); MNI Chicago PMI, November (67.0 expected, 68.4 in October); Conference Board Consumer Confidence Index, November (110.0 expected, 113.8 in October)</p><p><blockquote><li><b>星期二：</b>9月FHFA房价指数环比（预期为1.2%，8月为1.0%）；S&amp;P CoreLogic Case-Shiller 20城综合指数，9月环比（预期1.30%，8月1.17%）；S&amp;P CoreLogic Case-Shiller 20城市综合指数，9月（上月为19.66%）；11月MNI芝加哥PMI（预期67.0，10月68.4）；世界大型企业联合会11月消费者信心指数（预期110.0，10月113.8）</li></blockquote></p><p></li>  <li><b>Wednesday:</b>MBA Mortgage Applications, November 26 (1.8% during prior week); ADP Employment Change, November (515,000 expected, 571,000 in October); Markit U.S. Manufacturing PMI, November final (59.1 during prior month); Construction Spending, month-over-month, October (0.5% expected, -0.5% in September); ISM Manufacturing, November (61.0 expected, 60.8 in October); Federal Reserve releases Beige Book</p><p><blockquote><li><b>星期三：</b>MBA抵押贷款申请，11月26日（前一周为1.8%）；11月ADP就业变化（预期51.5万人，10月57.1万人）；Markit美国制造业PMI，11月终值（上月为59.1）；10月份建筑支出环比（预期0.5%，9月份-0.5%）；ISM制造业，11月（预期61.0，10月60.8）；美联储发布褐皮书</li></blockquote></p><p></li>  <li><b>Thursday:</b>Challenger job cuts, November (-71.7% in October); Initial jobless claims, week ended Nov. 27 (199,000 during prior week); Continuing claims, Nov. 20 (2.049 during prior week)</p><p><blockquote><li><b>星期四：</b>挑战者裁员，11月（10月为-71.7%）；截至11月27日当周首次申请失业救济人数（前一周为199,000人）；11月20日持续申请失业救济人数（前一周为2.049）</li></blockquote></p><p></li>  <li><b>Friday:</b>Change in non-farm payrolls, November (500,000 expected, 531,000 in October); Unemployment rate, November (4.5% expected, 4.6% in October); Average Hourly Earnings, month-over-month, November (0.4% expected, 0.4% in October); Average Hourly Earnings, year-over-year, November (5.0% expected, 4.9% in October); Markit U.S. Services PMI, November final (57.0 in prior print); Markit U.S. Composite PMI, November final (56.5 in prior print); ISM Services Index, November (65.0 expected, 66.7 in October); Factory Orders, October (0.5% expected, 0.2% in September); Durable Goods Orders, October final (-0.5% in prior print)</p><p><blockquote><li><b>星期五：</b>11月非农就业人数变化（预期50万，10月53.1万）；11月失业率（预期4.5%，10月4.6%）；11月平均时薪环比（预期0.4%，10月0.4%）；11月平均时薪同比（预期5.0%，10月4.9%）；Markit美国服务业PMI，11月最终数据（上一期为57.0）；Markit美国综合PMI，11月最终数据（上一期为56.5）；ISM服务业指数，11月（预期65.0，10月66.7）；10月工厂订单（预期0.5%，9月0.2%）；耐用品订单，10月份最终（上次打印为-0.5%）</li></blockquote></p><p></li> </ul> Earnings calendar</p><p><blockquote>盈利日历</blockquote></p><p> <ul>  <li><b>Monday:</b><i>No notable reports scheduled for release</i></p><p><blockquote><ul><li><b>星期一：</b><i>没有计划发布值得注意的报告</i></li></ul></blockquote></p><p></li>  <li><b>Tuesday:</b>Salesforce.com (CRM) after market close</p><p><blockquote><li><b>星期二：</b>Salesforce.com(CRM)收盘后</li></blockquote></p><p></li>  <li><b>Wednesday:</b>PVH Corp. (PVH) after market close</p><p><blockquote><li><b>星期三：</b>PVH Corp.(PVH)收盘后</li></blockquote></p><p></li>  <li><b>Thursday:</b>Dollar General (DG), Kroger (KR) before market open; Ulta Beauty (ULTA) after market close</p><p><blockquote><li><b>星期四：</b>Dollar General(DG)、Kroger(KR)开盘前；Ulta Beauty(ULTA)收盘后</li></blockquote></p><p></li>  <li><b>Friday:</b><i>No notable reports scheduled for release</i></p><p><blockquote><li><b>星期五：</b><i>没有计划发布值得注意的报告</i></li></blockquote></p><p></li> </ul></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>November jobs report: What to know this week<blockquote>11月就业报告：本周需要了解什么</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovember jobs report: What to know this week<blockquote>11月就业报告：本周需要了解什么</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">yahoo</strong><span class=\"h-time small\">2021-11-29 07:06</span>\n</p>\n</h4>\n</header>\n<article>\n<p>As investors return from the Thanksgiving-shortened trading week, focus will shift to the U.S. labor market.</p><p><blockquote>随着投资者从感恩节缩短的交易周回归，焦点将转向美国劳动力市场。</blockquote></p><p> The Labor Department's monthly jobs report due for release on Friday is set to provide an updated snapshot of the strength in hiring and labor force participation in the U.S. economy. Consensus economists are looking for a half-million jobs to have returned in November, with the pace of hiring slowing only slightly from October's 531,000 gain. The unemployment rate is also expected to improve further to 4.5% from October's 4.6%, reaching the lowest level since March 2020.</p><p><blockquote>美国劳工部将于周五发布的月度就业报告将提供美国经济中招聘和劳动力参与实力的最新快照。经济学家一致认为，11月份将有50万个工作岗位回归，招聘速度仅较10月份的531,000个略有放缓。失业率也有望从10月的4.6%进一步改善至4.5%，达到2020年3月以来的最低水平。</blockquote></p><p> \"We expect non-farm payrolls to have risen by 500,000 in November, but the growing risk of a winter COVID wave and a dwindling supply of available workers will weigh on jobs growth soon,\" wrote Paul Ashworth, chief North America economist for Capital Economics, in a note last week.</p><p><blockquote>凯投宏观(Capital Economics)首席北美经济学家保罗·阿什沃斯(Paul Ashworth)写道：“我们预计11月份非农就业人数将增加50万人，但冬季新冠疫情风险不断增加以及可用工人供应减少将很快拖累就业增长。”在上周的一份报告中。</blockquote></p><p> \"Employment growth can’t continue at this pace for much longer unless the labor force stages a more notable recovery. If anything, labor supply could<i>worsen</i>over the coming months as the federal vaccine mandate covering 100 [million] workers begins on January 4,\" Ashworth added. \"That suggests wage growth will remain strong, and we expect a 0.4% [month-over-month] rise in average hourly earnings in October.\"</p><p><blockquote>“除非劳动力出现更显著的复苏，否则就业增长不可能以这种速度持续太久。如果说有什么不同的话，那就是劳动力供应可以<i>恶化</i>随着覆盖1亿工人的联邦疫苗授权于1月4日开始，未来几个月，”阿什沃斯补充道。“这表明工资增长将保持强劲，我们预计10月份平均时薪将[环比]增长0.4%。”</blockquote></p><p> On a year-over-year basis, average hourly earnings are expected to rise by 5.0%, accelerating even further after October's already marked 4.9% rise and representing the fastest wage growth rate since February.</p><p><blockquote>与去年同期相比，平均时薪预计将增长5.0%，继10月份已经显着增长4.9%之后进一步加速，这是自2月份以来最快的工资增长率。</blockquote></p><p> Growing average wages and a tight labor market — while a positive for consumers and their ability to spend — has also stoked concerns over persistent inflation. Last week's Personal Consumption Expenditures (PCE) deflator from the Bureau of Economic Analysis for October showed an annual jump of 5.0% in the index, or the biggest rise since 1990. And the core PCE, or the Fed's preferred inflation gauge stripping out volatile food and energy prices, rose by 4.1% year-over-year — the most in three decades.</p><p><blockquote>平均工资增长和劳动力市场紧张虽然对消费者及其消费能力有利，但也引发了人们对持续通胀的担忧。上周经济分析局公布的10月份个人消费支出(PCE)平减指数显示，该指数年率上涨5.0%，创1990年以来最大涨幅。核心PCE（即美联储首选的剔除波动较大的食品和能源价格的通胀指标）同比上涨4.1%，为三十年来的最高水平。</blockquote></p><p> Other recent data have homed in on the tight labor market and presaged a potentially strong November jobs report. Last week'sinitial jobless claims fell to a 52-year low of 199,000, taking out both the prior pandemic-era low and pre-pandemic average for new first-time filings. This served as yet another point underscoring the steep competition for labor among U.S. employers, with companies attempting to hire and retain their existing workforces amid widespread labor shortages.</p><p><blockquote>最近的其他数据集中在紧张的劳动力市场上，并预示着11月份就业报告可能强劲。上周首次申请失业救济人数降至19.9万人的52年低点，打破了之前大流行时期的低点和大流行前新首次申请失业救济人数的平均值。这再次凸显了美国雇主之间对劳动力的激烈竞争，在劳动力普遍短缺的情况下，公司试图雇用和留住现有劳动力。</blockquote></p><p> Even given these lingering scarcities, the labor force participation rate has yet to return to pre-pandemic levels. The civilian labor force was still down by nearly 3 million participants compared to February 2020, with lingering concerns over the virus and adesire by many working-age individuals to seek out new roles with better flexibility and benefitsstill keeping many individuals on the sidelines of the workforce. Consensus economists expect the labor force participation rate to tick up only slightly in November to reach 61.7%, growing from October's 61.6% but coming in well below the 63.3% rate from February 2020.</p><p><blockquote>即使考虑到这些挥之不去的短缺，劳动力参与率仍未恢复到大流行前的水平。与2020年2月相比，平民劳动力仍减少了近300万参与者，对病毒的担忧挥之不去，许多工作年龄的人渴望寻找具有更好灵活性和福利的新角色，这仍然使许多人处于劳动力的边缘。经济学家普遍预计，11月份劳动力参与率仅略有上升，达到61.7%，高于10月份的61.6%，但远低于2020年2月的63.3%。</blockquote></p><p> Returning the economy back to pre-pandemic labor force participation levels and ensuring job gains are seen equitably across different groups has become a key focus for the Federal Reserve. And the distance still left to make up on these fronts has also been the biggest factor keeping the Fed ultra-accommodative with its monetary policy support, even after a parade of hotter-than-expected inflation reports that would appear to warrant a more hawkish policy tilt and a quicker-than-expected hike to interest rates.Fed Chair Jerome Powell's renomination to remain as head of the central bankfurther suggests the Fed's focus on the labor market as a critical informing factor for monetary policy will remain.</p><p><blockquote>将经济恢复到大流行前的劳动力参与水平，并确保不同群体公平地看到就业增长，已成为美联储的一个重点关注点。在这些方面仍有待弥补的距离也是美联储货币政策支持保持超宽松的最大因素，即使在一系列高于预期的通胀报告似乎需要采取更强硬的政策倾斜美联储主席杰罗姆·鲍威尔再次被提名继续担任央行行长进一步表明，美联储将继续关注劳动力市场，将其作为货币政策的关键信息因素。</blockquote></p><p> \"Market views for future Fed rate increases have been pulled forward aggressively in response to evidence that elevated inflation pressures are likely to persist for longer,\" wrote Deutsche Bank economist Justin Weidner in a note last week. \"However, as Chair Powell's November press conference made evident, prospects for the labor market to return to maximum employment remain a critical consideration for when the Fed will eventually begin to actively tighten monetary policy.\"</p><p><blockquote>德意志银行经济学家贾斯汀·魏德纳(Justin Weidner)上周在一份报告中写道：“由于有证据表明通胀压力上升可能会持续更长时间，市场对美联储未来加息的看法已大幅提前。”“然而，正如鲍威尔主席11月新闻发布会所表明的那样，劳动力市场恢复最大就业的前景仍然是美联储最终何时开始积极收紧货币政策的关键考虑因素。”</blockquote></p><p> Economic calendar</p><p><blockquote>经济日历</blockquote></p><p> <ul>  <li><b>Monday:</b>Pending home sales, month-over-month, October (0.7% expected, -2.3% in September); Dallas Federal Reserve Manufacturing Activity Index, November (17.0 expected, 14.6 in October)</p><p><blockquote><ul><li><b>星期一：</b>10月份待售房屋环比（预期0.7%，9月份-2.3%）；11月达拉斯联储制造业活动指数（预期17.0，10月14.6）</li></ul></blockquote></p><p></p><p></li>  <li><b>Tuesday:</b>FHFA House Price Index, month-over-month, September (1.2% expected, 1.0% in August); S&amp;P CoreLogic Case-Shiller 20-City Composite Index, month-over-month, September (1.30% expected, 1.17% in August); S&amp;P CoreLogic Case-Shiller 20-City Composite Index, September (19.66% during prior month); MNI Chicago PMI, November (67.0 expected, 68.4 in October); Conference Board Consumer Confidence Index, November (110.0 expected, 113.8 in October)</p><p><blockquote><li><b>星期二：</b>9月FHFA房价指数环比（预期为1.2%，8月为1.0%）；S&amp;P CoreLogic Case-Shiller 20城综合指数，9月环比（预期1.30%，8月1.17%）；S&amp;P CoreLogic Case-Shiller 20城市综合指数，9月（上月为19.66%）；11月MNI芝加哥PMI（预期67.0，10月68.4）；世界大型企业联合会11月消费者信心指数（预期110.0，10月113.8）</li></blockquote></p><p></li>  <li><b>Wednesday:</b>MBA Mortgage Applications, November 26 (1.8% during prior week); ADP Employment Change, November (515,000 expected, 571,000 in October); Markit U.S. Manufacturing PMI, November final (59.1 during prior month); Construction Spending, month-over-month, October (0.5% expected, -0.5% in September); ISM Manufacturing, November (61.0 expected, 60.8 in October); Federal Reserve releases Beige Book</p><p><blockquote><li><b>星期三：</b>MBA抵押贷款申请，11月26日（前一周为1.8%）；11月ADP就业变化（预期51.5万人，10月57.1万人）；Markit美国制造业PMI，11月终值（上月为59.1）；10月份建筑支出环比（预期0.5%，9月份-0.5%）；ISM制造业，11月（预期61.0，10月60.8）；美联储发布褐皮书</li></blockquote></p><p></li>  <li><b>Thursday:</b>Challenger job cuts, November (-71.7% in October); Initial jobless claims, week ended Nov. 27 (199,000 during prior week); Continuing claims, Nov. 20 (2.049 during prior week)</p><p><blockquote><li><b>星期四：</b>挑战者裁员，11月（10月为-71.7%）；截至11月27日当周首次申请失业救济人数（前一周为199,000人）；11月20日持续申请失业救济人数（前一周为2.049）</li></blockquote></p><p></li>  <li><b>Friday:</b>Change in non-farm payrolls, November (500,000 expected, 531,000 in October); Unemployment rate, November (4.5% expected, 4.6% in October); Average Hourly Earnings, month-over-month, November (0.4% expected, 0.4% in October); Average Hourly Earnings, year-over-year, November (5.0% expected, 4.9% in October); Markit U.S. Services PMI, November final (57.0 in prior print); Markit U.S. Composite PMI, November final (56.5 in prior print); ISM Services Index, November (65.0 expected, 66.7 in October); Factory Orders, October (0.5% expected, 0.2% in September); Durable Goods Orders, October final (-0.5% in prior print)</p><p><blockquote><li><b>星期五：</b>11月非农就业人数变化（预期50万，10月53.1万）；11月失业率（预期4.5%，10月4.6%）；11月平均时薪环比（预期0.4%，10月0.4%）；11月平均时薪同比（预期5.0%，10月4.9%）；Markit美国服务业PMI，11月最终数据（上一期为57.0）；Markit美国综合PMI，11月最终数据（上一期为56.5）；ISM服务业指数，11月（预期65.0，10月66.7）；10月工厂订单（预期0.5%，9月0.2%）；耐用品订单，10月份最终（上次打印为-0.5%）</li></blockquote></p><p></li> </ul> Earnings calendar</p><p><blockquote>盈利日历</blockquote></p><p> <ul>  <li><b>Monday:</b><i>No notable reports scheduled for release</i></p><p><blockquote><ul><li><b>星期一：</b><i>没有计划发布值得注意的报告</i></li></ul></blockquote></p><p></li>  <li><b>Tuesday:</b>Salesforce.com (CRM) after market close</p><p><blockquote><li><b>星期二：</b>Salesforce.com(CRM)收盘后</li></blockquote></p><p></li>  <li><b>Wednesday:</b>PVH Corp. (PVH) after market close</p><p><blockquote><li><b>星期三：</b>PVH Corp.(PVH)收盘后</li></blockquote></p><p></li>  <li><b>Thursday:</b>Dollar General (DG), Kroger (KR) before market open; Ulta Beauty (ULTA) after market close</p><p><blockquote><li><b>星期四：</b>Dollar General(DG)、Kroger(KR)开盘前；Ulta Beauty(ULTA)收盘后</li></blockquote></p><p></li>  <li><b>Friday:</b><i>No notable reports scheduled for release</i></p><p><blockquote><li><b>星期五：</b><i>没有计划发布值得注意的报告</i></li></blockquote></p><p></li> </ul></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/november-jobs-report-what-to-know-this-week-144428419.html\">yahoo</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CRM":"赛富时"},"source_url":"https://finance.yahoo.com/news/november-jobs-report-what-to-know-this-week-144428419.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124072014","content_text":"As investors return from the Thanksgiving-shortened trading week, focus will shift to the U.S. labor market.\nThe Labor Department's monthly jobs report due for release on Friday is set to provide an updated snapshot of the strength in hiring and labor force participation in the U.S. economy. Consensus economists are looking for a half-million jobs to have returned in November, with the pace of hiring slowing only slightly from October's 531,000 gain. The unemployment rate is also expected to improve further to 4.5% from October's 4.6%, reaching the lowest level since March 2020.\n\"We expect non-farm payrolls to have risen by 500,000 in November, but the growing risk of a winter COVID wave and a dwindling supply of available workers will weigh on jobs growth soon,\" wrote Paul Ashworth, chief North America economist for Capital Economics, in a note last week.\n\"Employment growth can’t continue at this pace for much longer unless the labor force stages a more notable recovery. If anything, labor supply couldworsenover the coming months as the federal vaccine mandate covering 100 [million] workers begins on January 4,\" Ashworth added. \"That suggests wage growth will remain strong, and we expect a 0.4% [month-over-month] rise in average hourly earnings in October.\"\nOn a year-over-year basis, average hourly earnings are expected to rise by 5.0%, accelerating even further after October's already marked 4.9% rise and representing the fastest wage growth rate since February.\nGrowing average wages and a tight labor market — while a positive for consumers and their ability to spend — has also stoked concerns over persistent inflation. Last week's Personal Consumption Expenditures (PCE) deflator from the Bureau of Economic Analysis for October showed an annual jump of 5.0% in the index, or the biggest rise since 1990. And the core PCE, or the Fed's preferred inflation gauge stripping out volatile food and energy prices, rose by 4.1% year-over-year — the most in three decades.\nOther recent data have homed in on the tight labor market and presaged a potentially strong November jobs report. Last week'sinitial jobless claims fell to a 52-year low of 199,000, taking out both the prior pandemic-era low and pre-pandemic average for new first-time filings. This served as yet another point underscoring the steep competition for labor among U.S. employers, with companies attempting to hire and retain their existing workforces amid widespread labor shortages.\nEven given these lingering scarcities, the labor force participation rate has yet to return to pre-pandemic levels. The civilian labor force was still down by nearly 3 million participants compared to February 2020, with lingering concerns over the virus and adesire by many working-age individuals to seek out new roles with better flexibility and benefitsstill keeping many individuals on the sidelines of the workforce. Consensus economists expect the labor force participation rate to tick up only slightly in November to reach 61.7%, growing from October's 61.6% but coming in well below the 63.3% rate from February 2020.\nReturning the economy back to pre-pandemic labor force participation levels and ensuring job gains are seen equitably across different groups has become a key focus for the Federal Reserve. And the distance still left to make up on these fronts has also been the biggest factor keeping the Fed ultra-accommodative with its monetary policy support, even after a parade of hotter-than-expected inflation reports that would appear to warrant a more hawkish policy tilt and a quicker-than-expected hike to interest rates.Fed Chair Jerome Powell's renomination to remain as head of the central bankfurther suggests the Fed's focus on the labor market as a critical informing factor for monetary policy will remain.\n\"Market views for future Fed rate increases have been pulled forward aggressively in response to evidence that elevated inflation pressures are likely to persist for longer,\" wrote Deutsche Bank economist Justin Weidner in a note last week. \"However, as Chair Powell's November press conference made evident, prospects for the labor market to return to maximum employment remain a critical consideration for when the Fed will eventually begin to actively tighten monetary policy.\"\nEconomic calendar\n\nMonday:Pending home sales, month-over-month, October (0.7% expected, -2.3% in September); Dallas Federal Reserve Manufacturing Activity Index, November (17.0 expected, 14.6 in October)\nTuesday:FHFA House Price Index, month-over-month, September (1.2% expected, 1.0% in August); S&P CoreLogic Case-Shiller 20-City Composite Index, month-over-month, September (1.30% expected, 1.17% in August); S&P CoreLogic Case-Shiller 20-City Composite Index, September (19.66% during prior month); MNI Chicago PMI, November (67.0 expected, 68.4 in October); Conference Board Consumer Confidence Index, November (110.0 expected, 113.8 in October)\nWednesday:MBA Mortgage Applications, November 26 (1.8% during prior week); ADP Employment Change, November (515,000 expected, 571,000 in October); Markit U.S. Manufacturing PMI, November final (59.1 during prior month); Construction Spending, month-over-month, October (0.5% expected, -0.5% in September); ISM Manufacturing, November (61.0 expected, 60.8 in October); Federal Reserve releases Beige Book\nThursday:Challenger job cuts, November (-71.7% in October); Initial jobless claims, week ended Nov. 27 (199,000 during prior week); Continuing claims, Nov. 20 (2.049 during prior week)\nFriday:Change in non-farm payrolls, November (500,000 expected, 531,000 in October); Unemployment rate, November (4.5% expected, 4.6% in October); Average Hourly Earnings, month-over-month, November (0.4% expected, 0.4% in October); Average Hourly Earnings, year-over-year, November (5.0% expected, 4.9% in October); Markit U.S. Services PMI, November final (57.0 in prior print); Markit U.S. Composite PMI, November final (56.5 in prior print); ISM Services Index, November (65.0 expected, 66.7 in October); Factory Orders, October (0.5% expected, 0.2% in September); Durable Goods Orders, October final (-0.5% in prior print)\n\nEarnings calendar\n\nMonday:No notable reports scheduled for release\nTuesday:Salesforce.com (CRM) after market close\nWednesday:PVH Corp. (PVH) after market close\nThursday:Dollar General (DG), Kroger (KR) before market open; Ulta Beauty (ULTA) after market close\nFriday:No notable reports scheduled for release","news_type":1,"symbols_score_info":{"CRM":0.9}},"isVote":1,"tweetType":1,"viewCount":66,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600509540,"gmtCreate":1638166461076,"gmtModify":1638166548065,"author":{"id":"4099680250879430","authorId":"4099680250879430","name":"lomenet65","avatar":"https://static.tigerbbs.com/a92a300242412a0d7cd11dbac51daaab","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099680250879430","idStr":"4099680250879430"},"themes":[],"title":"","htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600509540","repostId":"1111346348","repostType":4,"isVote":1,"tweetType":1,"viewCount":91,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600509184,"gmtCreate":1638166443491,"gmtModify":1638166546679,"author":{"id":"4099680250879430","authorId":"4099680250879430","name":"lomenet65","avatar":"https://static.tigerbbs.com/a92a300242412a0d7cd11dbac51daaab","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099680250879430","idStr":"4099680250879430"},"themes":[],"title":"","htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600509184","repostId":"1197312559","repostType":4,"repost":{"id":"1197312559","kind":"news","pubTimestamp":1638164401,"share":"https://www.laohu8.com/m/news/1197312559?lang=zh_CN&edition=full","pubTime":"2021-11-29 13:40","market":"us","language":"en","title":"India's Paytm falls as net loss widens on higher expense<blockquote>费用增加导致净亏损扩大，印度Paytm股价下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1197312559","media":"Reuters","summary":"Shares in India's One 97 Communications Ltd, the parent of Paytm, fell as much as 4.6% on Monday aft","content":"<p>Shares in India's One 97 Communications Ltd, the parent of Paytm, fell as much as 4.6% on Monday after the fintech company's net loss for its second quarter widened due to a rise in expenses.</p><p><blockquote>Paytm母公司印度One 97 Communications Ltd的股价周一下跌4.6%，此前这家金融科技公司第二季度净亏损因费用增加而扩大。</blockquote></p><p> In its first earnings report since going public earlier this month, the company said expenses jumped 37.1% to 15.99 billion rupees and consolidated net loss increased to 4.74 billion rupees ($63.31 million) from 4.37 billion rupees a year ago.</p><p><blockquote>该公司在本月早些时候上市以来的首份财报中表示，费用跃升37.1%至159.9亿卢比，综合净亏损从一年前的43.7亿卢比增至47.4亿卢比（6331万美元）。</blockquote></p><p> Its revenue from operations, however, surged 63.6% to 10.86 billion rupees for the quarter ended September.</p><p><blockquote>然而，截至9月份的季度，其运营收入飙升63.6%，达到108.6亿卢比。</blockquote></p><p> \"Some of the line items in our payment business are not just profit generating but free cash flow generating,\" founder and chief executive Vijay Shekhar Sharma said in an earnings call for investors on Saturday.</p><p><blockquote>创始人兼首席执行官Vijay Shekhar Sharma在周六为投资者举行的财报看涨期权上表示：“我们支付业务中的一些项目不仅产生利润，还产生自由现金流。”</blockquote></p><p> Paytm, which counts China's Ant Group and Japan's SoftBank Group among its backers, raised $2.5 billion this month in India's biggest initial public offering, but made a dismal debut on the stock exchanges.</p><p><blockquote>Paytm的支持者包括蚂蚁集团和软银集团，本月在印度最大的首次公开募股中筹集了25亿美元，但在印度证券交易所的首次亮相却表现惨淡。</blockquote></p><p> While the stock has recouped some of the losses suffered during the debut, it still remained nearly 21% below its IPO offer price of 2,150 rupees.</p><p><blockquote>尽管该股已经收复了首次亮相时遭受的部分损失，但仍比IPO发行价2,150卢比低近21%。</blockquote></p><p> \"I'm looking to sell the shares as soon as the price goes up,\" said Bansidhar Bhatia from east Indian city of Kolkata, who bought Paytm shares at the issue price.</p><p><blockquote>“我希望一旦价格上涨就出售股票，”来自印度东部城市加尔各答的Bansidhar Bhatia表示，他以发行价购买了Paytm股票。</blockquote></p><p> \"I don't see long-term value in the stock and its price is very high compared to the company's business model.\"</p><p><blockquote>“我认为该股票没有长期价值，与公司的商业模式相比，其价格非常高。”</blockquote></p><p> As of 0430 GMT, Paytm shares were trading down 0.3% at 1,776 rupees.</p><p><blockquote>截至格林威治标准时间0430，Paytm股价下跌0.3%，至1776卢比。</blockquote></p><p> ($1 = 74.8660 Indian rupees)</p><p><blockquote>（1美元=74.8660印度卢比）</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>India's Paytm falls as net loss widens on higher expense<blockquote>费用增加导致净亏损扩大，印度Paytm股价下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIndia's Paytm falls as net loss widens on higher expense<blockquote>费用增加导致净亏损扩大，印度Paytm股价下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-29 13:40</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Shares in India's One 97 Communications Ltd, the parent of Paytm, fell as much as 4.6% on Monday after the fintech company's net loss for its second quarter widened due to a rise in expenses.</p><p><blockquote>Paytm母公司印度One 97 Communications Ltd的股价周一下跌4.6%，此前这家金融科技公司第二季度净亏损因费用增加而扩大。</blockquote></p><p> In its first earnings report since going public earlier this month, the company said expenses jumped 37.1% to 15.99 billion rupees and consolidated net loss increased to 4.74 billion rupees ($63.31 million) from 4.37 billion rupees a year ago.</p><p><blockquote>该公司在本月早些时候上市以来的首份财报中表示，费用跃升37.1%至159.9亿卢比，综合净亏损从一年前的43.7亿卢比增至47.4亿卢比（6331万美元）。</blockquote></p><p> Its revenue from operations, however, surged 63.6% to 10.86 billion rupees for the quarter ended September.</p><p><blockquote>然而，截至9月份的季度，其运营收入飙升63.6%，达到108.6亿卢比。</blockquote></p><p> \"Some of the line items in our payment business are not just profit generating but free cash flow generating,\" founder and chief executive Vijay Shekhar Sharma said in an earnings call for investors on Saturday.</p><p><blockquote>创始人兼首席执行官Vijay Shekhar Sharma在周六为投资者举行的财报看涨期权上表示：“我们支付业务中的一些项目不仅产生利润，还产生自由现金流。”</blockquote></p><p> Paytm, which counts China's Ant Group and Japan's SoftBank Group among its backers, raised $2.5 billion this month in India's biggest initial public offering, but made a dismal debut on the stock exchanges.</p><p><blockquote>Paytm的支持者包括蚂蚁集团和软银集团，本月在印度最大的首次公开募股中筹集了25亿美元，但在印度证券交易所的首次亮相却表现惨淡。</blockquote></p><p> While the stock has recouped some of the losses suffered during the debut, it still remained nearly 21% below its IPO offer price of 2,150 rupees.</p><p><blockquote>尽管该股已经收复了首次亮相时遭受的部分损失，但仍比IPO发行价2,150卢比低近21%。</blockquote></p><p> \"I'm looking to sell the shares as soon as the price goes up,\" said Bansidhar Bhatia from east Indian city of Kolkata, who bought Paytm shares at the issue price.</p><p><blockquote>“我希望一旦价格上涨就出售股票，”来自印度东部城市加尔各答的Bansidhar Bhatia表示，他以发行价购买了Paytm股票。</blockquote></p><p> \"I don't see long-term value in the stock and its price is very high compared to the company's business model.\"</p><p><blockquote>“我认为该股票没有长期价值，与公司的商业模式相比，其价格非常高。”</blockquote></p><p> As of 0430 GMT, Paytm shares were trading down 0.3% at 1,776 rupees.</p><p><blockquote>截至格林威治标准时间0430，Paytm股价下跌0.3%，至1776卢比。</blockquote></p><p> ($1 = 74.8660 Indian rupees)</p><p><blockquote>（1美元=74.8660印度卢比）</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/indias-paytm-falls-4-6-041045248.html\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BABA":"阿里巴巴","09988":"阿里巴巴-W"},"source_url":"https://finance.yahoo.com/news/indias-paytm-falls-4-6-041045248.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197312559","content_text":"Shares in India's One 97 Communications Ltd, the parent of Paytm, fell as much as 4.6% on Monday after the fintech company's net loss for its second quarter widened due to a rise in expenses.\nIn its first earnings report since going public earlier this month, the company said expenses jumped 37.1% to 15.99 billion rupees and consolidated net loss increased to 4.74 billion rupees ($63.31 million) from 4.37 billion rupees a year ago.\nIts revenue from operations, however, surged 63.6% to 10.86 billion rupees for the quarter ended September.\n\"Some of the line items in our payment business are not just profit generating but free cash flow generating,\" founder and chief executive Vijay Shekhar Sharma said in an earnings call for investors on Saturday.\nPaytm, which counts China's Ant Group and Japan's SoftBank Group among its backers, raised $2.5 billion this month in India's biggest initial public offering, but made a dismal debut on the stock exchanges.\nWhile the stock has recouped some of the losses suffered during the debut, it still remained nearly 21% below its IPO offer price of 2,150 rupees.\n\"I'm looking to sell the shares as soon as the price goes up,\" said Bansidhar Bhatia from east Indian city of Kolkata, who bought Paytm shares at the issue price.\n\"I don't see long-term value in the stock and its price is very high compared to the company's business model.\"\nAs of 0430 GMT, Paytm shares were trading down 0.3% at 1,776 rupees.\n($1 = 74.8660 Indian rupees)","news_type":1,"symbols_score_info":{"BABA":0.9,"09988":0.9}},"isVote":1,"tweetType":1,"viewCount":209,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600509393,"gmtCreate":1638166418418,"gmtModify":1638166418418,"author":{"id":"4099680250879430","authorId":"4099680250879430","name":"lomenet65","avatar":"https://static.tigerbbs.com/a92a300242412a0d7cd11dbac51daaab","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099680250879430","idStr":"4099680250879430"},"themes":[],"title":"","htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/600509393","repostId":"1176629484","repostType":4,"repost":{"id":"1176629484","kind":"news","pubTimestamp":1638165609,"share":"https://www.laohu8.com/m/news/1176629484?lang=zh_CN&edition=full","pubTime":"2021-11-29 14:00","market":"sg","language":"en","title":"Digital Core REIT to raise $600 mln in Singapore's biggest IPO this year<blockquote>Digital Core REIT将在新加坡今年最大的IPO中筹集6亿美元</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1176629484","media":"Reuters","summary":"Digital Core REIT, sponsored by U.S.-listed Digital Realty Trust(DLR.N), is set to raise $600 millio","content":"<p>Digital Core REIT, sponsored by U.S.-listed Digital Realty Trust(DLR.N), is set to raise $600 million in an initial public offering (IPO) in Singapore, the largest listing in the city-state this year, the company said in its prospectus on Monday.</p><p><blockquote>Digital Core REIT由在美国上市的Digital Realty Trust(DLR.N)发起。该公司在周一的招股说明书中表示，该公司将在新加坡首次公开募股(IPO)中筹集6亿美元，这是今年新加坡最大的一次上市。</blockquote></p><p> The Real Estate Investment Trust (REIT), which owns 10 freehold data centres in the United States and Canada worth around $1.4 billion, is issuing 682 million units at $0.88 per a piece, excluding a greenshoe option worth $47 million.</p><p><blockquote>该房地产投资信托基金(REIT)在美国和加拿大拥有10个永久业权数据中心，价值约14亿美元，将以每份0.88美元的价格发行6.82亿个单位，不包括价值4700万美元的绿鞋期权。</blockquote></p><p> Blackrock Inc(BLK.N), Eastspring Investments, Fullerton Fund Management and AIA Investment Management are among the cornerstone investors in the IPO. The cornerstone investors are buying shares worth $365 million or 61% of the total offer.</p><p><blockquote>贝莱德公司（BLK.N）、瀚亚投资、富勒顿基金管理公司和友邦保险投资管理公司是此次IPO的基石投资者。基石投资者购买了价值3.65亿美元的股票，占总报价的61%。</blockquote></p><p> The retail component, around $12 million, opens on Monday. Shares totalling $223 million are being placed to other institutions.</p><p><blockquote>零售部分价值约1200万美元，将于周一开业。总计2.23亿美元的股票正在配售给其他机构。</blockquote></p><p> The REIT will list on Dec. 6.</p><p><blockquote>该房地产投资信托基金将于12月6日上市。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Digital Core REIT to raise $600 mln in Singapore's biggest IPO this year<blockquote>Digital Core REIT将在新加坡今年最大的IPO中筹集6亿美元</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDigital Core REIT to raise $600 mln in Singapore's biggest IPO this year<blockquote>Digital Core REIT将在新加坡今年最大的IPO中筹集6亿美元</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-29 14:00</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Digital Core REIT, sponsored by U.S.-listed Digital Realty Trust(DLR.N), is set to raise $600 million in an initial public offering (IPO) in Singapore, the largest listing in the city-state this year, the company said in its prospectus on Monday.</p><p><blockquote>Digital Core REIT由在美国上市的Digital Realty Trust(DLR.N)发起。该公司在周一的招股说明书中表示，该公司将在新加坡首次公开募股(IPO)中筹集6亿美元，这是今年新加坡最大的一次上市。</blockquote></p><p> The Real Estate Investment Trust (REIT), which owns 10 freehold data centres in the United States and Canada worth around $1.4 billion, is issuing 682 million units at $0.88 per a piece, excluding a greenshoe option worth $47 million.</p><p><blockquote>该房地产投资信托基金(REIT)在美国和加拿大拥有10个永久业权数据中心，价值约14亿美元，将以每份0.88美元的价格发行6.82亿个单位，不包括价值4700万美元的绿鞋期权。</blockquote></p><p> Blackrock Inc(BLK.N), Eastspring Investments, Fullerton Fund Management and AIA Investment Management are among the cornerstone investors in the IPO. The cornerstone investors are buying shares worth $365 million or 61% of the total offer.</p><p><blockquote>贝莱德公司（BLK.N）、瀚亚投资、富勒顿基金管理公司和友邦保险投资管理公司是此次IPO的基石投资者。基石投资者购买了价值3.65亿美元的股票，占总报价的61%。</blockquote></p><p> The retail component, around $12 million, opens on Monday. Shares totalling $223 million are being placed to other institutions.</p><p><blockquote>零售部分价值约1200万美元，将于周一开业。总计2.23亿美元的股票正在配售给其他机构。</blockquote></p><p> The REIT will list on Dec. 6.</p><p><blockquote>该房地产投资信托基金将于12月6日上市。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/markets/funds/digital-core-reit-raise-600-mln-singapores-biggest-ipo-this-year-2021-11-29/\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BX":"黑石"},"source_url":"https://www.reuters.com/markets/funds/digital-core-reit-raise-600-mln-singapores-biggest-ipo-this-year-2021-11-29/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176629484","content_text":"Digital Core REIT, sponsored by U.S.-listed Digital Realty Trust(DLR.N), is set to raise $600 million in an initial public offering (IPO) in Singapore, the largest listing in the city-state this year, the company said in its prospectus on Monday.\nThe Real Estate Investment Trust (REIT), which owns 10 freehold data centres in the United States and Canada worth around $1.4 billion, is issuing 682 million units at $0.88 per a piece, excluding a greenshoe option worth $47 million.\nBlackrock Inc(BLK.N), Eastspring Investments, Fullerton Fund Management and AIA Investment Management are among the cornerstone investors in the IPO. The cornerstone investors are buying shares worth $365 million or 61% of the total offer.\nThe retail component, around $12 million, opens on Monday. Shares totalling $223 million are being placed to other institutions.\nThe REIT will list on Dec. 6.","news_type":1,"symbols_score_info":{"BX":0.9}},"isVote":1,"tweetType":1,"viewCount":401,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877019080,"gmtCreate":1637839260614,"gmtModify":1637839260745,"author":{"id":"4099680250879430","authorId":"4099680250879430","name":"lomenet65","avatar":"https://static.tigerbbs.com/a92a300242412a0d7cd11dbac51daaab","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099680250879430","idStr":"4099680250879430"},"themes":[],"title":"","htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877019080","repostId":"875066277","repostType":1,"repost":{"id":875066277,"gmtCreate":1637589677869,"gmtModify":1637592109060,"author":{"id":"3506828071299216","authorId":"3506828071299216","name":"新能源洒水车","avatar":"https://static.tigerbbs.com/6be9dbe6a55511108da1da5b7571ca8e","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3506828071299216","idStr":"3506828071299216"},"themes":[],"title":"ET7的爆款潜质！","htmlText":"<a href=\"https://laohu8.com/S/NIO\">$蔚来(NIO)$</a>ET7的颜值只有在亲临眼前才会感受到，惊艳又耐看，太棒了！无比期待！！创新·质感·韵味我们终于有了世界级的设计。","listText":"<a href=\"https://laohu8.com/S/NIO\">$蔚来(NIO)$</a>ET7的颜值只有在亲临眼前才会感受到，惊艳又耐看，太棒了！无比期待！！创新·质感·韵味我们终于有了世界级的设计。","text":"$蔚来(NIO)$ET7的颜值只有在亲临眼前才会感受到，惊艳又耐看，太棒了！无比期待！！创新·质感·韵味我们终于有了世界级的设计。","images":[{"img":"https://static.tigerbbs.com/e152ecaaae92aa198f2a9e453013ea00","width":"4032","height":"3024"},{"img":"https://static.tigerbbs.com/37d3bd9c0b3d1d92c5965bef1050e6a3","width":"3024","height":"4032"},{"img":"https://static.tigerbbs.com/200c3945312c671c4180d88a8a8418c5","width":"4032","height":"3024"}],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875066277","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":9,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":111,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877037676,"gmtCreate":1637839115222,"gmtModify":1637839115222,"author":{"id":"4099680250879430","authorId":"4099680250879430","name":"lomenet65","avatar":"https://static.tigerbbs.com/a92a300242412a0d7cd11dbac51daaab","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099680250879430","idStr":"4099680250879430"},"themes":[],"title":"","htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877037676","repostId":"2186364681","repostType":4,"isVote":1,"tweetType":1,"viewCount":588,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877037829,"gmtCreate":1637839107103,"gmtModify":1637839107103,"author":{"id":"4099680250879430","authorId":"4099680250879430","name":"lomenet65","avatar":"https://static.tigerbbs.com/a92a300242412a0d7cd11dbac51daaab","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099680250879430","idStr":"4099680250879430"},"themes":[],"title":"","htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877037829","repostId":"2186364681","repostType":4,"repost":{"id":"2186364681","kind":"news","pubTimestamp":1637829030,"share":"https://www.laohu8.com/m/news/2186364681?lang=zh_CN&edition=full","pubTime":"2021-11-25 16:30","market":"sg","language":"en","title":"Dyson terminates relationship with Malaysian supplier ATA over labour<blockquote>戴森因劳工问题终止与马来西亚供应商ATA的关系</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2186364681","media":"Reuters","summary":"(REUTERS) - Dyson has terminated its relationship with supplier ATA IMS Berhad following an audit of","content":"<p><div> (REUTERS) - Dyson has terminated its relationship with supplier ATA IMS Berhad following an audit of the Malaysian company's labour practices and allegations by a whistleblower, the British firm famed...</p><p><blockquote><div>（路透社）-戴森终止了与供应商ATA IMS Berhad的关系，此前这家马来西亚公司对其劳工行为进行了审计，并受到了举报人的指控...</div></blockquote></p><p>  <a href=\"http://www.straitstimes.com/asia/se-asia/dyson-terminates-relationship-with-malaysian-supplier-ata-over-labour\">网页链接</a>  </div> </p><p><blockquote><a href=\"http://www.straitstimes.com/asia/se-asia/dyson-terminates-relationship-with-malaysian-supplier-ata-over-labour\">网页连接</a></blockquote></p><p></p>","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dyson terminates relationship with Malaysian supplier ATA over labour<blockquote>戴森因劳工问题终止与马来西亚供应商ATA的关系</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDyson terminates relationship with Malaysian supplier ATA over labour<blockquote>戴森因劳工问题终止与马来西亚供应商ATA的关系</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-25 16:30</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> (REUTERS) - Dyson has terminated its relationship with supplier ATA IMS Berhad following an audit of the Malaysian company's labour practices and allegations by a whistleblower, the British firm famed...</p><p><blockquote><div>（路透社）-戴森终止了与供应商ATA IMS Berhad的关系，此前这家马来西亚公司对其劳工行为进行了审计，并受到了举报人的指控...</div></blockquote></p><p>  <a href=\"http://www.straitstimes.com/asia/se-asia/dyson-terminates-relationship-with-malaysian-supplier-ata-over-labour\">网页链接</a>  </div> </p><p><blockquote><a href=\"http://www.straitstimes.com/asia/se-asia/dyson-terminates-relationship-with-malaysian-supplier-ata-over-labour\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.straitstimes.com/asia/se-asia/dyson-terminates-relationship-with-malaysian-supplier-ata-over-labour\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"http://www.straitstimes.com/asia/se-asia/dyson-terminates-relationship-with-malaysian-supplier-ata-over-labour","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2186364681","content_text":"(REUTERS) - Dyson has terminated its relationship with supplier ATA IMS Berhad following an audit of the Malaysian company's labour practices and allegations by a whistleblower, the British firm famed for its high-tech vacuum cleaners told Reuters.\nDyson said it had commissioned an audit of working conditions at ATA earlier this year, the results of which were received on Oct 4.\nIn addition, it was informed in September of a whistleblower making allegations about unacceptable actions by ATA staff and immediately commissioned an international law firm to undertake a further investigation, Dyson said.\n\"Despite intense engagement over the past six weeks, we have not seen sufficient progress and have already removed some production lines,\" Dyson said in a statement to Reuters.\n\"We have now terminated our relationship with six months of contractual notice.\"\nATA, which makes parts for Dyson's vacuum cleaners and air purifiers, did not immediately respond to a Reuters' request for comment.\nAccording to ATA, Dyson accounts for almost 80 per cent of its revenue.\nATA had in May denied allegations of forced labour at its factories after a prominent rights activist said US authorities were going to scrutinise the company's work practices.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":855,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877034772,"gmtCreate":1637839069981,"gmtModify":1637839069981,"author":{"id":"4099680250879430","authorId":"4099680250879430","name":"lomenet65","avatar":"https://static.tigerbbs.com/a92a300242412a0d7cd11dbac51daaab","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099680250879430","idStr":"4099680250879430"},"themes":[],"title":"","htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877034772","repostId":"2185354679","repostType":4,"isVote":1,"tweetType":1,"viewCount":340,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876452186,"gmtCreate":1637346443365,"gmtModify":1637346443513,"author":{"id":"4099680250879430","authorId":"4099680250879430","name":"lomenet65","avatar":"https://static.tigerbbs.com/a92a300242412a0d7cd11dbac51daaab","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099680250879430","idStr":"4099680250879430"},"themes":[],"title":"","htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876452186","repostId":"1196590230","repostType":4,"repost":{"id":"1196590230","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637333792,"share":"https://www.laohu8.com/m/news/1196590230?lang=zh_CN&edition=full","pubTime":"2021-11-19 22:56","market":"us","language":"en","title":"Intuit jumped over 12% in morning trading after showing its better than expected financial report<blockquote>Intuit公布好于预期的财务报告后早盘上涨逾12%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1196590230","media":"Tiger Newspress","summary":"Intuit jumped over 12% in morning trading after showing its better than expected financial report.Th","content":"<p>Intuit jumped over 12% in morning trading after showing its better than expected financial report.<img src=\"https://static.tigerbbs.com/42f4f450ee6253bb16a6e0f50267fdbc\" tg-width=\"770\" tg-height=\"560\" width=\"100%\" height=\"auto\">The company announced the latest quarterly financial report, showing that the quarterly sales were 2.01 billion US dollars, an increase of 51.7% year-on-year and higher than the expected 1.81 billion US dollars; The revenue was USD 1.53/share, up 62.77% year-on-year, and higher than the expected USD 0.99/share.</p><p><blockquote>Intuit在公布好于预期的财务报告后，早盘交易中股价上涨超过12%。公司公布最新季度财报显示，季度销售额20.1亿美元，同比增长51.7%，高于预期的18.1亿美元；营收1.53美元/股，同比增长62.77%，高于预期的0.99美元/股。</blockquote></p><p> CEO Sasan Goodarzi remarked that the company is \"off to a strong start in fiscal year 2022, delivering on our strategy of becoming an AI-driven expert platform powering the prosperity of consumers and small businesses.\"</p><p><blockquote>首席执行官Sasan Goodarzi表示，该公司“在2022财年取得了良好的开局，实现了我们成为人工智能驱动的专家平台的战略，为消费者和小企业的繁荣提供动力。”</blockquote></p><p> Added Goodarzi,\"We continue to see strong momentum and proof that our Big Bets are further positioning us for durable growth in the future, and we're delighted that Mailchimp has joined Intuit.\"</p><p><blockquote>Goodarzi补充道：“我们继续看到强劲的势头，并证明我们的大赌注进一步为我们未来的持久增长做好了准备，我们很高兴Mailchimp加入Intuit。”</blockquote></p><p> Goodarzi was referring to the company's acquisition of The Rocket Science Group LLC, makers of Mailchimp, for $12.4 billion in cash, a deal completed November 1st.</p><p><blockquote>Goodarzi指的是该公司以124亿美元现金收购Mailchimp制造商Rocket Science Group LLC，该交易于11月1日完成。</blockquote></p><p> Intuit's purchase of Mailchimp was for the purpose of enabling Intuit it to build an \"end-to-end customer growth platform\" for SMBs.</p><p><blockquote>Intuit收购Mailchimp的目的是让Intuit it能够为中小企业建立一个“端到端的客户增长平台”。</blockquote></p><p> Intuit expects that its SMB platform will enable businesses to go online, market, manage customer relationships and get analytics while managing cash flow.</p><p><blockquote>Intuit预计，其SMB平台将使企业能够上网、营销、管理客户关系并获得分析，同时管理现金流。</blockquote></p><p> Revenue in the three months ended in September rose 57%, year over year, to $2 billion, yielding a net profit of $1.53 a share, excluding some costs.</p><p><blockquote>截至9月份的三个月收入同比增长57%，达到20亿美元，不包括一些成本，每股净利润为1.53美元。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intuit jumped over 12% in morning trading after showing its better than expected financial report<blockquote>Intuit公布好于预期的财务报告后早盘上涨逾12%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntuit jumped over 12% in morning trading after showing its better than expected financial report<blockquote>Intuit公布好于预期的财务报告后早盘上涨逾12%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-19 22:56</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Intuit jumped over 12% in morning trading after showing its better than expected financial report.<img src=\"https://static.tigerbbs.com/42f4f450ee6253bb16a6e0f50267fdbc\" tg-width=\"770\" tg-height=\"560\" width=\"100%\" height=\"auto\">The company announced the latest quarterly financial report, showing that the quarterly sales were 2.01 billion US dollars, an increase of 51.7% year-on-year and higher than the expected 1.81 billion US dollars; The revenue was USD 1.53/share, up 62.77% year-on-year, and higher than the expected USD 0.99/share.</p><p><blockquote>Intuit在公布好于预期的财务报告后，早盘交易中股价上涨超过12%。公司公布最新季度财报显示，季度销售额20.1亿美元，同比增长51.7%，高于预期的18.1亿美元；营收1.53美元/股，同比增长62.77%，高于预期的0.99美元/股。</blockquote></p><p> CEO Sasan Goodarzi remarked that the company is \"off to a strong start in fiscal year 2022, delivering on our strategy of becoming an AI-driven expert platform powering the prosperity of consumers and small businesses.\"</p><p><blockquote>首席执行官Sasan Goodarzi表示，该公司“在2022财年取得了良好的开局，实现了我们成为人工智能驱动的专家平台的战略，为消费者和小企业的繁荣提供动力。”</blockquote></p><p> Added Goodarzi,\"We continue to see strong momentum and proof that our Big Bets are further positioning us for durable growth in the future, and we're delighted that Mailchimp has joined Intuit.\"</p><p><blockquote>Goodarzi补充道：“我们继续看到强劲的势头，并证明我们的大赌注进一步为我们未来的持久增长做好了准备，我们很高兴Mailchimp加入Intuit。”</blockquote></p><p> Goodarzi was referring to the company's acquisition of The Rocket Science Group LLC, makers of Mailchimp, for $12.4 billion in cash, a deal completed November 1st.</p><p><blockquote>Goodarzi指的是该公司以124亿美元现金收购Mailchimp制造商Rocket Science Group LLC，该交易于11月1日完成。</blockquote></p><p> Intuit's purchase of Mailchimp was for the purpose of enabling Intuit it to build an \"end-to-end customer growth platform\" for SMBs.</p><p><blockquote>Intuit收购Mailchimp的目的是让Intuit it能够为中小企业建立一个“端到端的客户增长平台”。</blockquote></p><p> Intuit expects that its SMB platform will enable businesses to go online, market, manage customer relationships and get analytics while managing cash flow.</p><p><blockquote>Intuit预计，其SMB平台将使企业能够上网、营销、管理客户关系并获得分析，同时管理现金流。</blockquote></p><p> Revenue in the three months ended in September rose 57%, year over year, to $2 billion, yielding a net profit of $1.53 a share, excluding some costs.</p><p><blockquote>截至9月份的三个月收入同比增长57%，达到20亿美元，不包括一些成本，每股净利润为1.53美元。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INTU":"财捷"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196590230","content_text":"Intuit jumped over 12% in morning trading after showing its better than expected financial report.The company announced the latest quarterly financial report, showing that the quarterly sales were 2.01 billion US dollars, an increase of 51.7% year-on-year and higher than the expected 1.81 billion US dollars; The revenue was USD 1.53/share, up 62.77% year-on-year, and higher than the expected USD 0.99/share.\nCEO Sasan Goodarzi remarked that the company is \"off to a strong start in fiscal year 2022, delivering on our strategy of becoming an AI-driven expert platform powering the prosperity of consumers and small businesses.\"\nAdded Goodarzi,\"We continue to see strong momentum and proof that our Big Bets are further positioning us for durable growth in the future, and we're delighted that Mailchimp has joined Intuit.\"\nGoodarzi was referring to the company's acquisition of The Rocket Science Group LLC, makers of Mailchimp, for $12.4 billion in cash, a deal completed November 1st.\nIntuit's purchase of Mailchimp was for the purpose of enabling Intuit it to build an \"end-to-end customer growth platform\" for SMBs.\nIntuit expects that its SMB platform will enable businesses to go online, market, manage customer relationships and get analytics while managing cash flow.\nRevenue in the three months ended in September rose 57%, year over year, to $2 billion, yielding a net profit of $1.53 a share, excluding some costs.","news_type":1,"symbols_score_info":{"INTU":0.9}},"isVote":1,"tweetType":1,"viewCount":236,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876452034,"gmtCreate":1637346420709,"gmtModify":1637346421831,"author":{"id":"4099680250879430","authorId":"4099680250879430","name":"lomenet65","avatar":"https://static.tigerbbs.com/a92a300242412a0d7cd11dbac51daaab","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099680250879430","idStr":"4099680250879430"},"themes":[],"title":"","htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876452034","repostId":"1140202544","repostType":4,"repost":{"id":"1140202544","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637335119,"share":"https://www.laohu8.com/m/news/1140202544?lang=zh_CN&edition=full","pubTime":"2021-11-19 23:18","market":"us","language":"en","title":"FuelCell stock jumped 6% in morning trading<blockquote>FuelCell股价早盘上涨6%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1140202544","media":"Tiger Newspress","summary":"FuelCell stock jumped 6% in morning trading.This mid-cap manufacturer of fuel cell power plants has ","content":"<p>FuelCell stock jumped 6% in morning trading.This mid-cap manufacturer of fuel cell power plants has been a laggard but according to the charts, that could soon change.</p><p><blockquote>FuelCell股价早盘上涨6%。这家中型燃料电池发电厂制造商一直落后，但根据图表，这种情况可能很快就会改变。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/421866dda5989cc2911e70ca2b2af943\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FuelCell stock jumped 6% in morning trading<blockquote>FuelCell股价早盘上涨6%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFuelCell stock jumped 6% in morning trading<blockquote>FuelCell股价早盘上涨6%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-19 23:18</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>FuelCell stock jumped 6% in morning trading.This mid-cap manufacturer of fuel cell power plants has been a laggard but according to the charts, that could soon change.</p><p><blockquote>FuelCell股价早盘上涨6%。这家中型燃料电池发电厂制造商一直落后，但根据图表，这种情况可能很快就会改变。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/421866dda5989cc2911e70ca2b2af943\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FCEL":"燃料电池能源"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140202544","content_text":"FuelCell stock jumped 6% in morning trading.This mid-cap manufacturer of fuel cell power plants has been a laggard but according to the charts, that could soon change.","news_type":1,"symbols_score_info":{"FCEL":0.9}},"isVote":1,"tweetType":1,"viewCount":219,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":878819888,"gmtCreate":1637164606200,"gmtModify":1637164606200,"author":{"id":"4099680250879430","authorId":"4099680250879430","name":"lomenet65","avatar":"https://static.tigerbbs.com/a92a300242412a0d7cd11dbac51daaab","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099680250879430","authorIdStr":"4099680250879430"},"themes":[],"title":"","htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/878819888","repostId":"2183079472","repostType":4,"isVote":1,"tweetType":1,"viewCount":522,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877037829,"gmtCreate":1637839107103,"gmtModify":1637839107103,"author":{"id":"4099680250879430","authorId":"4099680250879430","name":"lomenet65","avatar":"https://static.tigerbbs.com/a92a300242412a0d7cd11dbac51daaab","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099680250879430","authorIdStr":"4099680250879430"},"themes":[],"title":"","htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877037829","repostId":"2186364681","repostType":4,"isVote":1,"tweetType":1,"viewCount":855,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600509393,"gmtCreate":1638166418418,"gmtModify":1638166418418,"author":{"id":"4099680250879430","authorId":"4099680250879430","name":"lomenet65","avatar":"https://static.tigerbbs.com/a92a300242412a0d7cd11dbac51daaab","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099680250879430","authorIdStr":"4099680250879430"},"themes":[],"title":"","htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/600509393","repostId":"1176629484","repostType":4,"isVote":1,"tweetType":1,"viewCount":401,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606508423,"gmtCreate":1638889763914,"gmtModify":1638889763970,"author":{"id":"4099680250879430","authorId":"4099680250879430","name":"lomenet65","avatar":"https://static.tigerbbs.com/a92a300242412a0d7cd11dbac51daaab","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099680250879430","authorIdStr":"4099680250879430"},"themes":[],"title":"","htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606508423","repostId":"2189476639","repostType":2,"isVote":1,"tweetType":1,"viewCount":1906,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871296974,"gmtCreate":1637072355612,"gmtModify":1637072471261,"author":{"id":"4099680250879430","authorId":"4099680250879430","name":"lomenet65","avatar":"https://static.tigerbbs.com/a92a300242412a0d7cd11dbac51daaab","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099680250879430","authorIdStr":"4099680250879430"},"themes":[],"title":"","htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":1,"link":"https://laohu8.com/post/871296974","repostId":"879685998","repostType":1,"repost":{"id":879685998,"gmtCreate":1636717423433,"gmtModify":1636720509188,"author":{"id":"3548388348794551","authorId":"3548388348794551","name":"问就是加仓up","avatar":"https://static.tigerbbs.com/4e98ddf789d46c5627f944fc581c0fe9","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3548388348794551","authorIdStr":"3548388348794551"},"themes":[],"title":"又上车了蔚来","htmlText":"昨晚买了点蔚来期权，其实也没啥，就是感觉看图好像好不错，感觉可以试试，所以就上车了，这种老情人系列的股票，真的是看一次买一次，不过大部分时候都是赚不到啥钱，不过有特斯拉二次上车点成功，这次蔚来打算也在试试，当然你可能说前几天我还不是说不考虑蔚来了吗。投机人的眼中，一句话的有效期，大概在说完之后就结束了。关于蔚来的财报，没啥好评价的，没想到的就是明年居然可以交付三款车型，目前蔚来的速度，真的感觉慢，希望赶紧加速吧， 而且我还是担心，明年的新车交付量能不能爆发性增长，目前这个进度真的太稳了（俗称慢），基本面没啥亮点，其实从股价也能看出来，就是 在震荡。不过最近股价持续贴着20日线拉升，所以想进去看看有没有啥机会。买了9张112月17号到期的45的看涨期权。最近的走势，其实和中概股整个板块的走势都比较相似，没有走出独立会趋势，感觉可以博弈一下，最大的可亏损就是这些本金了。关于这个操作，期权依然是赌突破，没有其他的想法，基本面无甚重大变化。成功了赚钱，不成功就割肉了，选择45股价的原因就是比较谨慎，同时今年的nio day在17号之前，并且月期权流动性高，就这么多看法。目前蔚来股价走势还是相对较弱，未来能不能实现持续上涨，还是需要持续观察。<a target=\"_blank\" href=\"https://laohu8.com/S/NIO\">$蔚来(NIO)$</a>&nbsp;<a target=\"_blank\" href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$</a>&nbsp;<a target=\"_blank\" href=\"https://laohu8.com/S/XPEV\">$小鹏汽车(XPEV)$</a>&nbsp;","listText":"昨晚买了点蔚来期权，其实也没啥，就是感觉看图好像好不错，感觉可以试试，所以就上车了，这种老情人系列的股票，真的是看一次买一次，不过大部分时候都是赚不到啥钱，不过有特斯拉二次上车点成功，这次蔚来打算也在试试，当然你可能说前几天我还不是说不考虑蔚来了吗。投机人的眼中，一句话的有效期，大概在说完之后就结束了。关于蔚来的财报，没啥好评价的，没想到的就是明年居然可以交付三款车型，目前蔚来的速度，真的感觉慢，希望赶紧加速吧， 而且我还是担心，明年的新车交付量能不能爆发性增长，目前这个进度真的太稳了（俗称慢），基本面没啥亮点，其实从股价也能看出来，就是 在震荡。不过最近股价持续贴着20日线拉升，所以想进去看看有没有啥机会。买了9张112月17号到期的45的看涨期权。最近的走势，其实和中概股整个板块的走势都比较相似，没有走出独立会趋势，感觉可以博弈一下，最大的可亏损就是这些本金了。关于这个操作，期权依然是赌突破，没有其他的想法，基本面无甚重大变化。成功了赚钱，不成功就割肉了，选择45股价的原因就是比较谨慎，同时今年的nio day在17号之前，并且月期权流动性高，就这么多看法。目前蔚来股价走势还是相对较弱，未来能不能实现持续上涨，还是需要持续观察。<a target=\"_blank\" href=\"https://laohu8.com/S/NIO\">$蔚来(NIO)$</a>&nbsp;<a target=\"_blank\" href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$</a>&nbsp;<a target=\"_blank\" href=\"https://laohu8.com/S/XPEV\">$小鹏汽车(XPEV)$</a>&nbsp;","text":"昨晚买了点蔚来期权，其实也没啥，就是感觉看图好像好不错，感觉可以试试，所以就上车了，这种老情人系列的股票，真的是看一次买一次，不过大部分时候都是赚不到啥钱，不过有特斯拉二次上车点成功，这次蔚来打算也在试试，当然你可能说前几天我还不是说不考虑蔚来了吗。投机人的眼中，一句话的有效期，大概在说完之后就结束了。关于蔚来的财报，没啥好评价的，没想到的就是明年居然可以交付三款车型，目前蔚来的速度，真的感觉慢，希望赶紧加速吧， 而且我还是担心，明年的新车交付量能不能爆发性增长，目前这个进度真的太稳了（俗称慢），基本面没啥亮点，其实从股价也能看出来，就是 在震荡。不过最近股价持续贴着20日线拉升，所以想进去看看有没有啥机会。买了9张112月17号到期的45的看涨期权。最近的走势，其实和中概股整个板块的走势都比较相似，没有走出独立会趋势，感觉可以博弈一下，最大的可亏损就是这些本金了。关于这个操作，期权依然是赌突破，没有其他的想法，基本面无甚重大变化。成功了赚钱，不成功就割肉了，选择45股价的原因就是比较谨慎，同时今年的nio day在17号之前，并且月期权流动性高，就这么多看法。目前蔚来股价走势还是相对较弱，未来能不能实现持续上涨，还是需要持续观察。$蔚来(NIO)$ $特斯拉(TSLA)$ $小鹏汽车(XPEV)$","images":[{"img":"https://static.tigerbbs.com/64e50cc330c1f83ac651dd842d1cda80","width":"442","height":"543"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879685998","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":68,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603566092,"gmtCreate":1638429065241,"gmtModify":1638429065315,"author":{"id":"4099680250879430","authorId":"4099680250879430","name":"lomenet65","avatar":"https://static.tigerbbs.com/a92a300242412a0d7cd11dbac51daaab","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099680250879430","authorIdStr":"4099680250879430"},"themes":[],"title":"","htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603566092","repostId":"1101300146","repostType":2,"repost":{"id":"1101300146","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638428501,"share":"https://www.laohu8.com/m/news/1101300146?lang=zh_CN&edition=full","pubTime":"2021-12-02 15:01","market":"us","language":"en","title":"Dow Jones futures rose nearly 1%, S&P 500 futures rose 0.85%, Nasdaq 100 futures rose 0.64%.<blockquote>道琼斯期货涨近1%，标普500期货涨0.85%，纳斯达克100期货涨0.64%。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1101300146","media":"Tiger Newspress","summary":"Dow Jones futures rose nearly 1%, S&P 500 futures rose 0.85%, Nasdaq 100 futures rose 0.64%.","content":"<p>Dow Jones futures rose&nbsp;nearly 1%, S&amp;P 500 futures rose 0.85%, Nasdaq 100 futures rose 0.64%.<img src=\"https://static.tigerbbs.com/7cc5fbc2c078d2e811d0be03d2c4950f\" tg-width=\"542\" tg-height=\"184\" width=\"100%\" height=\"auto\"></p><p><blockquote>道琼斯期货涨近1%，标普500期货涨0.85%，纳斯达克100期货涨0.64%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dow Jones futures rose nearly 1%, S&P 500 futures rose 0.85%, Nasdaq 100 futures rose 0.64%.<blockquote>道琼斯期货涨近1%，标普500期货涨0.85%，纳斯达克100期货涨0.64%。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDow Jones futures rose nearly 1%, S&P 500 futures rose 0.85%, Nasdaq 100 futures rose 0.64%.<blockquote>道琼斯期货涨近1%，标普500期货涨0.85%，纳斯达克100期货涨0.64%。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-02 15:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Dow Jones futures rose&nbsp;nearly 1%, S&amp;P 500 futures rose 0.85%, Nasdaq 100 futures rose 0.64%.<img src=\"https://static.tigerbbs.com/7cc5fbc2c078d2e811d0be03d2c4950f\" tg-width=\"542\" tg-height=\"184\" width=\"100%\" height=\"auto\"></p><p><blockquote>道琼斯期货涨近1%，标普500期货涨0.85%，纳斯达克100期货涨0.64%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101300146","content_text":"Dow Jones futures rose nearly 1%, S&P 500 futures rose 0.85%, Nasdaq 100 futures rose 0.64%.","news_type":1,"symbols_score_info":{"ESmain":0.9,"YMmain":0.9,"NQmain":0.9}},"isVote":1,"tweetType":1,"viewCount":1672,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876452034,"gmtCreate":1637346420709,"gmtModify":1637346421831,"author":{"id":"4099680250879430","authorId":"4099680250879430","name":"lomenet65","avatar":"https://static.tigerbbs.com/a92a300242412a0d7cd11dbac51daaab","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099680250879430","authorIdStr":"4099680250879430"},"themes":[],"title":"","htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876452034","repostId":"1140202544","repostType":4,"repost":{"id":"1140202544","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637335119,"share":"https://www.laohu8.com/m/news/1140202544?lang=zh_CN&edition=full","pubTime":"2021-11-19 23:18","market":"us","language":"en","title":"FuelCell stock jumped 6% in morning trading<blockquote>FuelCell股价早盘上涨6%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1140202544","media":"Tiger Newspress","summary":"FuelCell stock jumped 6% in morning trading.This mid-cap manufacturer of fuel cell power plants has ","content":"<p>FuelCell stock jumped 6% in morning trading.This mid-cap manufacturer of fuel cell power plants has been a laggard but according to the charts, that could soon change.</p><p><blockquote>FuelCell股价早盘上涨6%。这家中型燃料电池发电厂制造商一直落后，但根据图表，这种情况可能很快就会改变。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/421866dda5989cc2911e70ca2b2af943\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FuelCell stock jumped 6% in morning trading<blockquote>FuelCell股价早盘上涨6%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFuelCell stock jumped 6% in morning trading<blockquote>FuelCell股价早盘上涨6%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-19 23:18</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>FuelCell stock jumped 6% in morning trading.This mid-cap manufacturer of fuel cell power plants has been a laggard but according to the charts, that could soon change.</p><p><blockquote>FuelCell股价早盘上涨6%。这家中型燃料电池发电厂制造商一直落后，但根据图表，这种情况可能很快就会改变。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/421866dda5989cc2911e70ca2b2af943\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FCEL":"燃料电池能源"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140202544","content_text":"FuelCell stock jumped 6% in morning trading.This mid-cap manufacturer of fuel cell power plants has been a laggard but according to the charts, that could soon change.","news_type":1,"symbols_score_info":{"FCEL":0.9}},"isVote":1,"tweetType":1,"viewCount":219,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606507133,"gmtCreate":1638890108532,"gmtModify":1638890108532,"author":{"id":"4099680250879430","authorId":"4099680250879430","name":"lomenet65","avatar":"https://static.tigerbbs.com/a92a300242412a0d7cd11dbac51daaab","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099680250879430","authorIdStr":"4099680250879430"},"themes":[],"title":"","htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606507133","repostId":"606159835","repostType":1,"repost":{"id":606159835,"gmtCreate":1638845497223,"gmtModify":1638931778801,"author":{"id":"3527667596890271","authorId":"3527667596890271","name":"Buy_Sell","avatar":"https://static.tigerbbs.com/a5f0ed79a338c758a22e0b4ea13bf9d2","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3527667596890271","authorIdStr":"3527667596890271"},"themes":[],"title":"🚀【12月7日】市场看淡病毒风险，中概多数反弹，今天买点啥？","htmlText":"聊聊今日份的交易想法，包括对于大盘走势后续的看法？看涨/看跌哪只股票、晒晒单等等。 港股市场 12月7日，港股三大指数大幅高开，恒指涨1.52%，国指涨1.62%，恒生科技指数涨2.07%。 恒生科技指数开涨超2%，科技股普遍上扬；<a target=\"_blank\" href=\"https://laohu8.com/S/09988\">$阿里巴巴-SW(09988)$</a> 开涨8.25%，隔夜其<a target=\"_blank\" href=\"https://laohu8.com/S/BABA\">$阿里巴巴(BABA)$</a> 美股收涨逾10%；<a target=\"_blank\" href=\"https://laohu8.com/S/09888\">$百度集团-SW(09888)$</a> 涨7.5%，<a target=\"_blank\" href=\"https://laohu8.com/S/03690\">$美团-W(03690)$</a> 涨超3%，<a target=\"_blank\" href=\"https://laohu8.com/S/00700\">$腾讯控股(00700)$</a> 、<a target=\"_blank\" href=\"https://laohu8.com/S/01024\">$快手-W(01024)$</a> 均涨超2%； 港股市场汽车股高开。其中，<a target=\"_blank\" href=\"https://laohu8.com/S/00708\">$恒大汽车(00708)$</a> 涨超5%，五菱汽车、理想汽车-W涨超3%，吉利汽车、长城汽车涨超2%，广汽集团、小鹏汽车-W、比亚迪等均涨超1%； 中国恒大开涨6.63%，昨日公司公告称决议设立中国恒大集团风险化解委员会；","listText":"聊聊今日份的交易想法，包括对于大盘走势后续的看法？看涨/看跌哪只股票、晒晒单等等。 港股市场 12月7日，港股三大指数大幅高开，恒指涨1.52%，国指涨1.62%，恒生科技指数涨2.07%。 恒生科技指数开涨超2%，科技股普遍上扬；<a target=\"_blank\" href=\"https://laohu8.com/S/09988\">$阿里巴巴-SW(09988)$</a> 开涨8.25%，隔夜其<a target=\"_blank\" href=\"https://laohu8.com/S/BABA\">$阿里巴巴(BABA)$</a> 美股收涨逾10%；<a target=\"_blank\" href=\"https://laohu8.com/S/09888\">$百度集团-SW(09888)$</a> 涨7.5%，<a target=\"_blank\" href=\"https://laohu8.com/S/03690\">$美团-W(03690)$</a> 涨超3%，<a target=\"_blank\" href=\"https://laohu8.com/S/00700\">$腾讯控股(00700)$</a> 、<a target=\"_blank\" href=\"https://laohu8.com/S/01024\">$快手-W(01024)$</a> 均涨超2%； 港股市场汽车股高开。其中，<a target=\"_blank\" href=\"https://laohu8.com/S/00708\">$恒大汽车(00708)$</a> 涨超5%，五菱汽车、理想汽车-W涨超3%，吉利汽车、长城汽车涨超2%，广汽集团、小鹏汽车-W、比亚迪等均涨超1%； 中国恒大开涨6.63%，昨日公司公告称决议设立中国恒大集团风险化解委员会；","text":"聊聊今日份的交易想法，包括对于大盘走势后续的看法？看涨/看跌哪只股票、晒晒单等等。 港股市场 12月7日，港股三大指数大幅高开，恒指涨1.52%，国指涨1.62%，恒生科技指数涨2.07%。 恒生科技指数开涨超2%，科技股普遍上扬；$阿里巴巴-SW(09988)$ 开涨8.25%，隔夜其$阿里巴巴(BABA)$ 美股收涨逾10%；$百度集团-SW(09888)$ 涨7.5%，$美团-W(03690)$ 涨超3%，$腾讯控股(00700)$ 、$快手-W(01024)$ 均涨超2%； 港股市场汽车股高开。其中，$恒大汽车(00708)$ 涨超5%，五菱汽车、理想汽车-W涨超3%，吉利汽车、长城汽车涨超2%，广汽集团、小鹏汽车-W、比亚迪等均涨超1%； 中国恒大开涨6.63%，昨日公司公告称决议设立中国恒大集团风险化解委员会；","images":[{"img":"https://static.tigerbbs.com/bef7c1191d263cbe5867f805bf92d02d","width":"240","height":"240"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606159835","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"subType":2,"comments":[],"imageCount":2,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2499,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606502862,"gmtCreate":1638889918652,"gmtModify":1638889918756,"author":{"id":"4099680250879430","authorId":"4099680250879430","name":"lomenet65","avatar":"https://static.tigerbbs.com/a92a300242412a0d7cd11dbac51daaab","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099680250879430","authorIdStr":"4099680250879430"},"themes":[],"title":"","htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606502862","repostId":"873111072","repostType":1,"repost":{"id":873111072,"gmtCreate":1636879722614,"gmtModify":1636940228507,"author":{"id":"3572212908677301","authorId":"3572212908677301","name":"JayceLee","avatar":"https://static.tigerbbs.com/697be0b87a439db9bb3e696889951c59","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572212908677301","authorIdStr":"3572212908677301"},"themes":[],"title":"Options Trade Ideas","htmlText":"Weekly Trade Ideas Boeing (<a target=\"_blank\" href=\"https://laohu8.com/S/BA\">$波音(BA)$</a>)The weekly chart is currently closed near the downtrend line. Watch for a potential breakout or rejection back to the support zone below which held nicely multiple times.In the daily chart, the price has been consolidating between 217 to 227.If breakthrough 225.24,&nbsp;my target zone is 235-239.67.If fall beyond 212.79, my target zone is 204.80-207.03.iShares Russell 2000 ETF (<a target=\"_blank\" href=\"https://laohu8.com/S/IWM\">$罗素2000指数ETF(IWM)$</a>)After a breakout from close to 1-year consolidation, we are seeing a pullback from the all-time high. Watch for trend continuation higher or falling back to retest the breakout level.In the daily chart, we are seeing 2 inside bars as the price consolidate","listText":"Weekly Trade Ideas Boeing (<a target=\"_blank\" href=\"https://laohu8.com/S/BA\">$波音(BA)$</a>)The weekly chart is currently closed near the downtrend line. Watch for a potential breakout or rejection back to the support zone below which held nicely multiple times.In the daily chart, the price has been consolidating between 217 to 227.If breakthrough 225.24,&nbsp;my target zone is 235-239.67.If fall beyond 212.79, my target zone is 204.80-207.03.iShares Russell 2000 ETF (<a target=\"_blank\" href=\"https://laohu8.com/S/IWM\">$罗素2000指数ETF(IWM)$</a>)After a breakout from close to 1-year consolidation, we are seeing a pullback from the all-time high. Watch for trend continuation higher or falling back to retest the breakout level.In the daily chart, we are seeing 2 inside bars as the price consolidate","text":"Weekly Trade Ideas Boeing ($波音(BA)$)The weekly chart is currently closed near the downtrend line. Watch for a potential breakout or rejection back to the support zone below which held nicely multiple times.In the daily chart, the price has been consolidating between 217 to 227.If breakthrough 225.24, my target zone is 235-239.67.If fall beyond 212.79, my target zone is 204.80-207.03.iShares Russell 2000 ETF ($罗素2000指数ETF(IWM)$)After a breakout from close to 1-year consolidation, we are seeing a pullback from the all-time high. Watch for trend continuation higher or falling back to retest the breakout level.In the daily chart, we are seeing 2 inside bars as the price consolidate","images":[{"img":"https://static.tigerbbs.com/f71b745209d69116541a279c1a67aafd","width":"688","height":"318"},{"img":"https://static.tigerbbs.com/b284906dc8d3cf7e9e8fc7101fad62c3","width":"688","height":"318"},{"img":"https://static.tigerbbs.com/649c8568e1b2d907f88e482ea097946d","width":"688","height":"297"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/873111072","isVote":2,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"vote":{"id":1604,"gmtBegin":1636879722613,"gmtEnd":1637370026856,"type":1,"upper":3,"title":"Which idea you like?","choices":[{"id":5883,"sort":1,"name":"BA","userSize":70,"voted":false},{"id":5884,"sort":2,"name":"IWM","userSize":20,"voted":false},{"id":5885,"sort":3,"name":"NIO","userSize":107,"voted":false},{"id":5886,"sort":4,"name":"TDOC","userSize":52,"voted":false},{"id":5887,"sort":5,"name":"XPEV","userSize":56,"voted":false},{"id":5888,"sort":6,"name":"ZM","userSize":25,"voted":false}]},"comments":[],"imageCount":11,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2881,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603565331,"gmtCreate":1638429308826,"gmtModify":1638429308914,"author":{"id":"4099680250879430","authorId":"4099680250879430","name":"lomenet65","avatar":"https://static.tigerbbs.com/a92a300242412a0d7cd11dbac51daaab","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099680250879430","authorIdStr":"4099680250879430"},"themes":[],"title":"","htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603565331","repostId":"1170912005","repostType":4,"isVote":1,"tweetType":1,"viewCount":1747,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}